Scientific Sessions 2020 Speaker Disclosure List

AC.CVS.96: Coronary Microvascular Disease and Approaches to Ischemia and Non-Obstructive Coronary Arteries (INOCA)

DESCRIPTION:

Approximately one-half of patients undergoing diagnostic coronary angiography for typical chest pain and/or ischemia by stress testing have no significant coronary stenosis. This challenging clinical syndrome is termed Ischemia and Non-Obstructive Coronary Arteries (INOCA). This session will provide practical advice for clinicians about managing patients with INOCA syndromes, including microvascular disease and coronary spasm.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular

physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Janet Wei

Other; Modest; Abbott.

Amir Lerman	A.Lerman: Other; Modest; Itamar medical, Volcano/Philips, Shahal, Weijian.
Viviany R Taqueti	None.
Tom Ford	None.
Puja K Mehta	None.
Nathaniel Smilowitz	None.
Harmony Reynolds	None.
Anais Hausvater	None.

AC.CVS.136: Anti-Inflammatory Therapies in Acute Myocardial Infarction: Where Are We in 2020?

DESCRIPTION:

The purpose of the session is to review the current knowledge about anti-inflammatory treatments in patients with acute myocardial infarction.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-106-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Samia Mora	Speaker/Speaker's Bureau; Quest Diagnostics.
Paul M Ridker	Honoraria; Novartis, J&J, Merck, Sanofi, Amarin, Peter Munk
	Toronto, Pfizer, Baim Institute, Cleveland Clinic, Civi
	Biopharm, Iqvia, Corvidia, Research Grant; Kowa, Novartis,
	NHLBI, Amarin.

Peter Libby	Other; Amgen, AstraZeneca, Esperion Therapeutics, Novo Nordisk, Kowa Pharmaceutical, Novartis, Pfizer, Sanofi- Regeneron, XBiotech, Inc., Corvidia Therapeutics, DalCor Pharmaceuticals, Merck, Olatec Therapeutics, Medimmune, Novartis, Baim Institute, Kancera.
Jean-Claude Tardif	Honoraria; Amarin, DalCor, Sanofi, Servier, Other; DalCor, Montreal Heart Institute, Ownership Interest; DalCor, Research Grant; Amarin, AstraZeneca, DalCor, Esperion, Ionis, RegenexBio, Sanofi, Servier.
Filippo Crea	Other; Biotronik, Speaker/Speaker's Bureau; Astra Zeneca, BMS, Servier, Amgen, Menarini, Biotronik.
Antonio Abbate	Honoraria; Merck, Serpin Pharma, GSK, Novo Nordisk, Cromos Pharma, Research Grant; Swedish Orphan Biovitrum, Olatec, Novartis.
Coleen A McNamara	None.

AC.EC.588: Debates in Cardiogenic Shock

DESCRIPTION:

State of the Art talk followed by 2 debates.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Judith S Hochman	J.S.Hochman: Employment; NYUSOM. Other Research Support; AstraZeneca Pharmaceuticals, LP, Arbor Pharmaceuticals, LLC. Other; Amgen, Inc. Research Grant; NIH/NHLBI grant support for ISCHEMIA Trial. Other; Abbott Vascular, Medtronic, Inc;, St Jude Medical, Inc, Volcano Corp, Merck Sharp & Dohme Corp, Omron Healthcare, Inc.
Venu Menon	None.
Vladimir Dzavik	None.
Holger Thiele	None.
Eric R Bates	None.

AC.CVS.251: Global A, B, Cs For Success of Implementation of High Sensitivity Cardiac Troponin Assays: Collaboration Between Clinical Practice and Laboratory Medicine

DESCRIPTION:

Using a global prospective of US and international emergency medicine and cardiology clinicians, in concert with laboratory medicine, the speakers will communicate and discuss practical implementation and clinical experience with high-sensitivity cardiac troponin (hs-cTnI, hs-cTnT) assays for early rule-out/rule-in of myocardial infarction, risk assessment, and primary/seconary prevention. Predicated on the Fourth Universal Definition of Myocardial Infarction guidelines and the AACC/IFCC clinical laboratory practice guidelines for defining quality control, normality and sexspecific 99th percentile upper reference limits to optimize patient safety, the speakers will use the evidence base literature and case studies to compare and contrast clinical and laboratory practice patterns.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Fred S Apple	Other; HyTest, LumiraDx, Brava Diagnostics, Siemens Healthineers, Abbott Diagnostics, Abbott POC, Siemens Healthcare, Roche Diagnostics, Beckman Coulter, Ortho-Clinical Diagnostics, Quidel, ET Healthcare, BD, Qorvo.
Allan S Jaffe	Other; Abbott, Siemens, ET Healthcare, Beckman-Coulter, Blade, Brava, Sphingotec, Quidel, Novartis.
Jennifer A Rymer	Research Grant; Boston Scientific, Abbott Medical.

CE.CVS.548: Cardio-Oncology, Meet Your New Neighbor: Immunology

DESCRIPTION:

Cardiovascular clinicians are increasingly facing the causes and effects of myocardial injury subsequent to immunologic-focused cancer therapy in their patients. This session will focus on those mechanistic interactions in order to optimize clinician knowledge in managing for myocardial injury.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Peter Liu	P.Liu: Other; Servier, Roche, Research Grant; Servier, Amgen, Boehringer Ingelheim.
Burkard Ludewig	B.Ludewig: Ownership Interest; Stromal Therapeutics AG.
Sakima A Smith	None.
Pilar Alcaide	None.
Joe-elie Salem	None.
Han Zhu	None.

Douglas G Tilley

None.

CE.EC.320: From Lab Rat to Fat Cat

DESCRIPTION:

This is an Early Career Session planned by the BCVS EC Committee on transitioning from a postdoctoral fellow to a new assistant professor and all the trials and tribulations that come with that move.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Priscila Y Sato	None.
Patricia K Nguyen	None.
Jason Karch	None.
Joseph A Hill	None.
Harpreet Singh	None.
Chiara Giannarelli	None.

CH.CVS.234: Can We Improve the Heart-Brain Connection in Congenital Heart Disease?

DESCRIPTION:

To describe recent advances in our understanding of the interaction between the infant's environment from fetal to post-natal surgical experiences and subsequent neurodevelopmental outcomes.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Mary Teresa	None.
Donofrio	
James W Gaynor	None.
George M Hoffman	None.
Amy Jo Lisanti	None.

CH.CVS.675: Application of Adult Cardiovascular Diagnostics & Therapies to the Congenital Heart Population

DESCRIPTION:

This session will focus on up to date information from adult cardiovascular medicine to inform the congenital heart disease providers.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 - 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for

completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-107-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Kendra Janel GrubbHonoraria; Medtronic, Ancora , Speaker/Speaker's Bureau;
Medtronic, Boston Scientific, Edwards Lifesciences.

Jean M Connors	Honoraria; Bristol-Meyers Squibb, Portola, Other Research Support; CSL Behring.
Giselle Adriana Baquero	Other; Boston Scientific.
David J Maron	Research Grant; National Heart, Lung, and Blood Institute.
Akshay S Desai	Honoraria; Boehringer-Ingelheim, Boston Scientific, Biofourmis, Relypsa, Regeneron, Alnylam, Cytokinetics, Merck, Novartis, AstraZeneca, Abbott, DalCor, Other Research Support; Novartis, AstraZeneca, Alnylam, Bayer.

CH.CVS.710: Practically Speaking, Building Best Practices for a Pediatric Preventive Cardiology Program

DESCRIPTION:

Educational session designed to engage participants and attendees in breakout session for further discussion.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Jacob Hartz	Honoraria; Today's Dietician (I spoke on a "Web Conference"), Boston Chapter of the Preventive Cardiovascular Nurses Association (Speaker at conference), Other; UpToDate Contributing Author, Research Grant; K23 Mentored Patient- Centered Career Development Award from NHLBI.
Elaine M Urbina	None.
Carissa Baker-Smith	None.
Amy Peterson	None.

CH.CVS.715: The Future is Now (or Coming Soon): Updates on New Technologies in Congenital Heart Care

DESCRIPTION:

This session will focus on providing updates on the "new" technologies that will be influencing (or soon influencing) congenital care.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Damien Kenny	Speaker/Speaker's Bureau; Occlutech.
Elisa Bradley	None.
Charles I Berul	None.
Brian D Feingold	None.

CH.CVS.726: Do as I Say, Not as I do: Health Policy and Guidelines in Pediatric Heart Disease

DESCRIPTION:

This session will focus on recent policies and guidelines in the field of pediatric cardiovascular disease - promises and pitfalls. Presentations will focus on both the positive aspects of such guidelines/policies and updates as to recent changes as well as potential unintended consequences, unanticipated challenges etc.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians The American Heart Association designates this live activity for a maximum of 0.75 *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Ritu Sachdeva	None.
Nancy Rudd	None.
Michael L O'Byrne	None.
Defne Magnetta	None.

CM.CVS.365: Prediabetes: Sitting in Your Waiting Room, Waiting for Your Management

DESCRIPTION:

The intersection between advances in managing diabetes for cardiovascular benefit, the mechanistic data revealing a pathologic continuum between diabetes and prediabetes and clinical scenarios cardiologists often encounter all point to increasing attention on "prediabetes" as an entity. Many basic and clinical questions exist regarding approaches to patients now increasingly identified as having prediabetes. Cardiologists and cardiology practices may be especially well suited to pursuing better understanding and management of these patients, as this session will address - explaining mechanisms underlying the prediabetes/diabetes continuum, clinical implications of prediabetes and potential clinical strategies for approaching such patients while more data emerges.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-108-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Pam R Taub	Research Grant; Amgen, Speaker/Speaker's Bureau; Boehringer Ingelheim, Sanofi/Regneraon, Amgen, Amarin, Stock Shareholder; Cardero Therapeutics.
Prakash C Deedwania	Research Grant; Boehringer, Sanofi.
Jorge Plutzky	Other; Amgen, Novartis, Novo Nordisk, sanofi, Vivus, Research Grant; Boehringer Ingelheim.
Jonathan Newman	Research Grant; National Institute of Health, Speaker/Speaker's Bureau; Creative Educational Concepts.
Henry N Ginsberg	Other; Merck , Silence Therapeutics, AstraZeneca, Janssen, Sanofi, Resverlogix, Kowa, Research Grant; Pfizer, Amgen.
Erin A Bohula	Honoraria; Servier, Novo Nordisk, Novartis, Merck, Amgen, Daiichi Sankyo, Medscape, NIH, Kowa, Lexicon, Research Grant; Merck, Amgen, Eisai, Astra Zeneca, Medicines Company, Novartis.
Jane E Reusch	None.

CM.CVS.605: New Glucose-Lowering Agents With CV Benefits: Working... But How?

DESCRIPTION:

Provide update on data and discussion regarding possible explanations for positive outcomes, which remain incompletely understood.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-109-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Subodh Verma	Honoraria; Amgen, Janssen, Boehringer-Ingelheim/Lilly, Merck, Bayer, Novonordisk, EOCI, HLS Therapeutics, Novartis, Sanofi, Sun Pharma, Toronto Knowledge Translation Working Group, AstraZeneca, Research Grant; Amgen, Boehringer- Ingelheim/Lilly, Bristol-Myers Squibb, HLS Therapeutics.
Naveed Sattar	Other; Amgen, AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Research Grant; Boehringer Ingelheim.
Jorge Plutzky	Other; Amgen, Novartis, Novo Nordisk, sanofi, Vivus, Research Grant; Boehringer Ingelheim.
Benjamin M Scirica	Expert Witness; AbbVie, Honoraria; Eisai, AstraZeneca, NovoNordick, Boerhinger Ingelheim, Other; Allergan, Research Grant; Eisai, Novartis, Merck.
A Michael Lincoff	Honoraria; Eli Lilly, Novo Nordisk, Research Grant; Astra Zeneca, Esperion, AbbVie, CSL, Novartis.

CM.CVS.659: Key Issues in Managing CV Disease in Diabetes: Tenet or Tenuous?

DESCRIPTION:

This session examines commonly accepted clinical perspectives in diabetes and how those views may (or may not) be challenged.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-110-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Samia Mora	Speaker/Speaker's Bureau; Quest Diagnostics.
Prakash C	Research Grant; Boehringer , Sanofi.
Deedwania II	

Neha Pagidipati	Honoraria; Esperion, Astra Zeneca, Boerhinger Ingelheim, Eli Lilly, Novo Nordisk, Research Grant; Amarin, Amgen, Novo Nordisk, Regeneron, Sanofi, Research Grant; Astra Zeneca, Baseline Study LLC, Boerhinger Ingelheim, Eli Lilly.
G Mancini	Honoraria; AstraZeneca, Novo Nordisk, Boeringher Ingelheim, Bayer, Other; Esperion, Novartis, Servier, HLS Therapeutics, Other Research Support; Merck, Speaker/Speaker's Bureau; Amgen, Sanofi.
Samuel Klein	Honoraria; Danone/Yakult, Merck, Research Grant; Johnson & Johnson, Stock Shareholder; Aspire Bariatrics.
CM.EC.616: How to Pursue Cardiometabolic Research in NIH-Funded Cohorts

DESCRIPTION:

The purpose of this session is to highlight and discuss ongoing NIH-funded cohort studies and to provide an opportunity for investigators to initiate new collaborations.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Eric Rimm	Honoraria; Flo, Research Grant; USDA, RWJF, Speaker/Speaker's Bureau; Culinary Institute of America, Stock Shareholder; Take Care Of.
April P Carson	Research Grant; Amgen, Inc
Mercedes R Carnethon	None.
Pamela L Lutsey	None.
Vasan S Ramachandran	None.

Erin Michos Carmen R Isasi Adolfo Correa None. None. None.

CO.CVS.180: A Potpourri of Cardiovascular Cases and Management Topics in Cardio-Oncology

DESCRIPTION:

The intent of this session is to provide 5 case-based discussions of various relevant topics in cardiooncology with a focus on management strategies.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-111-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Sunil Pauwaa	Honoraria; Pfizer, AstraZeneca, Novartis.
Kevin Michael	Other; Alnylam, Eidos.
Alexander	
John M Dimaio	Ownership Interest; Spectral MD, Inc
Sherry-Ann Brown	None.

Nimesh Patel	None.
Michael J. Reardon	None.
Borja Ibañez	None.
Ana I Casanegra	None.
Alvin Chandra	None.
Susan Kim	None.

CO.CVS.202: Rapid Fire: The Cardiovascular Lifestyle of a Cancer Patient – Finding a Balance!

DESCRIPTION:

This RAPID-FIRE presentation is aimed at educating attendees about the cardiovascular risks associated with cancer treatment modalities and strategies to prevent cardiovascular toxicity.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Susan Faye Dent	Honoraria; Novartis.
Tochi M Okwuosa	None.
Theresa M Beckie	None.
Kerryn Reding	None.
Jessica Scott	None.

CO.CVS.307: Novel Cardio-Metabolic Paradigms in Cardio-Oncology

DESCRIPTION:

The purpose of this session is to engage clinicians and scientists at the interface between cardiology and oncology in in a dialogue about discoveries and translational applications of cardiovascular metabolic concepts in this space.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Vlad G Zaha	Research Grant; Cancer Prevention Research Institute of Texas.
Lorenz H Lehmann	Expert Witness; Daiichi Sankyio, Servier, Senaca, Speaker/Speaker's Bureau; MSD.
Javid Moslehi	Honoraria; Pfizer, Novartis, Bristol Myers Squibb, Deciphera.
Alessandra Ghigo	Stock Shareholder; Kither Biotech, a spin-off company focused on the development of PI3K inhibitors for the treatment of respiratory diseases. Not pertinent to the content of the presentation

Aarti Asnani Evan Dale Abel Honoraria; UpToDate. None.

CO.CVS.792: Cardio-Oncology: From Clinical Outcomes to the Intersection of Molecular Mechanisms

DESCRIPTION:

Cardio-Oncology is a dynamic field. Learn about the new, bold and emerging ideas in the field.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-112-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Rudolf A De Boer Research Grant; AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk, Roche, Speaker/Speaker's Bureau; Abbott, AstraZeneca, Novartis, Roche.

Linda W Van Laake	Other; Abbott, Medtronic, Novartis, Roche, Sopachem, Vifor, Research Grant; Netherlands Heart Foundation, Health Holland, University Medical Center Utrecht, Technical University Eindhoven, Utrecht University.
David J Milan	Employment; Broadview Ventures.
Lavanya Kondapalli	None.
June Rhee	None.

CS.JS.811: Diversity and Inclusion in Cardiovascular Medicine: Planning for Success and Sustainability: AHA Joint Session with the American College of Cardiology

DESCRIPTION:

AHA Joint Session with the American College of Cardiology

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Clyde W Yancy Jr.	Other; Abbott, Inc, JAMA Network.
Quinn Capers IV	None.
lleana L Pina	None.
Dipti Itchhaporia	None.

CS.ME.101: Structural Racism as a Public Health Crisis (an American Heart Association and Association of Black Cardiologists session)

DESCRIPTION:

The session will feature two keynote talks followed by a robust discussion of racism as a public health crisis from the perspectives of national leaders from research, clinical care, public health and policy, education, and industry.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit[™]* from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliation
--

Ted Love	Employment; Global Blood Therapeutics, Stock Shareholder; Seattle Genetics Board Member, Royalty Pharma Board Member.
Mitchell S Elkind	Other; UpToDate, Other Research Support; BMS-Pfizer Alliance for Eliquis, Research Grant; Roche.
David R Williams	Research Grant; Kellogg Foundation.

Sonia Y AngellNone.Paula JohnsonNone.Michelle A AlbertNone.Lisa A CooperNone.Keith B ChurchwellNone.Hannah ValantineNone.Donald M Lloyd-None.JonesNones

CV19.ME.1453: Daily Recap & AHA COVID-19 Rapid Response Research Consortium: Early Results

DESCRIPTION:

Engaging conversation is surely to happen on the incoming results from the AHA Rapid Response COVID-19 Research Initiative.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.50 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Robert A Harrington	Other; WebMD, Ownership Interest; Element Science.
Michael R Bristow	Employment; Arca biopharma, Ownership Interest; Arca biopharma, Research Grant; AHA, Stock Shareholder; Arca biopharma.
Mina K Chung	Other; Elsevier Publishers, UpToDate, American Heart Association, Heart Rhythm Society, France ANR, American Board of Internal Medicine, Research Grant; American Heart Association, National Institutes of Health.
Rebekah L Gundry	None.

Michelle A Albert	None.
Jane E Freedman	None.
lleana L Pina	None.
Joseph Loscalzo	None.

CV19.ME.1478: Clinical and Public Health Impact of COVID-19 (International Focus)

DESCRIPTION:

This session will feature insights on COVID-19, cardiovascular disease, and outcomes from colleagues on the front lines of the COVID pandemic in affected countries across the globe: Australia/New Zealand, South Korea, China, Italy, Tanzania, and Brazil.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Xiang Cheng	None.
Seongwook Han	None.
Leonard Kritharides	None.
Ludhmila Hajjar	None.
Furio Colivicchi	None.
Ciro Indolfi	None.
Hendry Sawe	None.

EA.CVS.263: Arrhythmias in Sarcoidosis: from Bench to Bedside

DESCRIPTION:

Arrhythmias in Sarcoidosis: from Bench to Bedside

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Usha B Tedrow	Honoraria; Abbott , Biosense Webster, Medtronic, Other; Thermedical Inc.
Ron Blankstein	Research Grant; Amgen Inc, Astellas Inc.
Lynda E Rosenfeld	Other; Boston Scientific, Medtronic, Abbott, Stock Shareholder; Abbott.
Ashish Aneja Todd M Koelling	Honoraria; Myokardia Inc None.

EA.CVS.281: Cardiac Physiologic Pacing - When, How, and Where?

DESCRIPTION:

An interactive session to discuss how to access the distal conduction system for pacing. Important questions will be debated on utility in pacemaker and resynchronization therapy.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Pugazhendhi	Honoraria; Abbott, Biotronik, Boston Scientific, Other Research
Vijayaraman	Support; Medtronic, Speaker/Speaker's Bureau; Medtronic.
Mina K Chung	Other; Elsevier Publishers, UpToDate, American Heart Association, Heart Rhythm Society, France ANR, American Board of Internal Medicine, Research Grant; American Heart Association, National Institutes of Health.
Gaurav A Upadhyay	Honoraria; Abbott, Zoll Medical, Other; Medtronic, Biotronik.
Daniel Lustgarten	Honoraria; Farapulse, CardioFocus, Medtronic, Abbott.
Weijian Huang	None.

Kimberly SelzmanNone.Kalyanam ShivkumarNone.

EA.CVS.338: Postural Tachycardia Syndrome (POTS), Autonomic Dysfunction, and Vaso-Vagal Syncope: A Multi-Disciplinary Case Based Approach

DESCRIPTION:

Postural tachycardia syndrome is an increasingly recognized entity that can cause significant symptoms in affected patients. Autonomicdysfunction / autonomic neuropathy can lead to symptoms from neuropathic POTS, neurogenic orthostatic hypotension, and gastrointestinal disturbances among others. While Cardiologists are increasingly asked to consult on patients with POTS and orthostatic hypotension, there is a significant knowledge deficit in general leading to increasing referrals to specialized centers. In addition, there is a significant overlap with other disciplines, especially with Neurology. Case-based discussions from multiple perspectives and disciplines can be useful to highlight the diagnosis and management of these patients. Note: This session is OnDemand and will be available from the start of the conference November 13, 2020 at 9:00 am until January 4, 2021.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Satish R Raj	Honoraria; Theravance Biopharma, Academy for Continued Healthcare Learning, Spire Learning, Other; American Autonomic Society, Arena Pharmaceuticals.
Brian Olshansky	Honoraria; Boehringer Ingelheim, Respironics, Lundbeck, Amarin.
Kenneth A Mayuga	None.
David S Goldstein	None.
Amr F Barakat	None.

EA.CVS.370: Device Therapy and Arrhythmia Management in LVAD and Heart Transplant Recipients: An Inter-Disciplinary Approach

DESCRIPTION:

This session will discuss the arrhythmia issues that LVAD and heart transplant patients face. This is a growing population who are living longer and whom EPs are being asked to evaluate more often. This particular patient population adds a different dynamic as to how arrhythmias are managed and where the indications and utility of device therapy are. It is an emerging field with rapid advancement in knowledge, a published scientific statement in 2019, and one where interdisciplinary collaboration is critical. Having a session at AHA to provide up-to-date information on this topic would be extremely valuable to the audience. Each talk will be introduced by a brief case by moderator 3 (fellow in training)

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias.

Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health. Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-113-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Rakesh	Honoraria; Abbott Medical, Zoll Medical, Research Grant; Boston
Gopinathannair	Scientific, Speaker/Speaker's Bureau; Pfizer.
Jonathan W Dukes	Other Research Support; Boston Scientific, Speaker/Speaker's Bureau; Medtronic, Biotronik, Biosense Webster.
Edo Birati	Research Grant; Medtronic Ltd., Impulse Dynamics.
Marmar Vaseghi	None.
Jose A Joglar Sr.	None.

EA.CVS.650: Novel Technologies for Arrhythmia Detection: The Data Tsunami is Around the Corner

DESCRIPTION:

The use of wearable technologies will be discussed during this session, including their impact on patient management, potential medico-legal and ethical implications and the interface with social media.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.
Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Marco V Perez	Expert Witness; Boehringer - Ingelheim, Honoraria; AltaThera, Research Grant; NIH/NHLBI, Apple Inc
Miguel Angelo Leal	Other; Medtronic.
Khaldoun Tarakji	Honoraria; Medtronic, Boston Scientific, Alivecor.
Janet Han	Honoraria; Abbott, Medtronic.
Leslie Anne Saxon	None.
Richard L Page	None.
Paul D Varosy	None.

EA.CVS.697: Electrophysiology Guidelines and Expert Consensus Statements: Top 5 New Releases and Updates

DESCRIPTION:

This session will cover the most important new recommendations from the Electrophysiology focused guidelines that have been released in the last 2 years.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Usha Tedrow	Honoraria; Abbott, Biosense Webster, Medtronic, Other; Thermedical Inc.
Martin Stiles Michael D Ezekowitz II	Speaker/Speaker's Bureau; Boehringer Ingleheim. Other; Sanofi, Abbott, Boston Scientific, Biogen, Anthos Therapeutic, Alta Thera.
Kenneth A Ellenbogen	Honoraria; Abbott, Biosense Webster, Biotronik, Medtronic, Boston Scientific, Other Research Support; Kestra, Research Grant; Medtronic, Boston Scientific, Biosense Webster.

Hugh G Calkins	Honoraria; Biosense, Boston Scientific, Abbott Medical, Boehringer Ingelheim, Atricure, Medtronic.
Douglas L Packer	Other; Dr. D. Packer in the past 12 months has provided consulting services for Abbott \$0, Biosense Webster \$0, Inc., Biotronik <\$5000, Boston Scientific \$0, CardioFocus \$0, Johnson & Johnson \$0, MediaSphere, Royalties from Wiley & Sons, Oxford, and St. Jude Medical., Mayo Clinic and Drs. D. Packer and R. Robb have a financial interest in mapping technology. In accordance with the Bayh-Dole Act, this technology has been licensed to St. Jude Medical, and Mayo Clini, Research Grant; CardioInsight, CardioFocus, Endosense, Hansen Medical, Siemens, and Thermedical., Abbott/St. Jude Medical, NIH, Medtronic, Biosense Websters, Inc., Boston Scientific, and Robertson Foundation.
Cara Pellegrini Lin Y Chen	Other; Jazz Pharmaceuticals. None.

EA.FIS.776: Arrhythmia Research Summit: Arrhythmogenesis: From Bench to Bedside

DESCRIPTION:

Frontiers in Science: Arrhythmia Research Summit

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Peng-sheng Chen	Honoraria; Heart Rhythm Society, Other Research Support; University of Bordeaux, France, Medtronic Inc., Research Grant; National Institutes of Health.
Walter J Koch	None.
Steven Marx	None.
Rengasayee Veeraraghavan	None.
Niels Voigt	None.
Donald M Bers	None.
Birte Maura Greiser	None.

EA.FIS.778: Arrhythmia Research Summit: The Newest Algorithms for Arrhythmia Mapping and Diagnosis with Insights for Practicing EP

DESCRIPTION:

Frontiers in Science: Arrhythmia Research Summit

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Vadim V Fedorov	Research Grant; Abbott EP.
Mansour Razminia	Honoraria; Baylis, Abbott.
Mark J Niebauer	Other; Medtronic, Inc.
Kyoko Soejima	Honoraria; Abbott Japan, Boehringer Ingelheim, Speaker/Speaker's Bureau; Medtronic Japan, Daiichi Sankyo.
Jennifer N Avari Silva Jr.	Other; Cardialen, Ownership Interest; SentiAR, Research Grant; SentiAR, Abbott/St Jude Medical, AliveCor, Speaker/Speaker's Bureau; Abbott/St Jude Medical.

lgor R Efimov	Ownership Interest; Cardialen.
Hiroshi Nakagawa	Honoraria; Boston Scientific, Inc, Affera, Inc, Other; Biosense Wester, Inc, Fukuda Denshi, Japan Lifeline.
Natalia Trayanova	None.
Natasja de Groot	None.

EA.FIS.779: Arrhythmia Research Summit: Atrial Fibrillation - Translational Approaches

DESCRIPTION:

Frontiers in Science: Arrhythmia Research Summit

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Steven A Lubitz	Honoraria; BMS / Pfizer, Bayer AG, Blackstone life sciences, Research Grant; BMS / Pfizer, Bayer AG, Boehringer Ingelheim, IBM, Fitbit.
Renate B Schnabel Michael Markl	Honoraria; BMS/Pfizer. Other; Circle Cardiovascular Imaging, Other Research Support; Siemens Healthineers, Research Grant; Circle Cardiovascular Imaging, Cryolife Inc

Other; Elsevier Publishers, UpToDate, American Heart Association, Heart Rhythm Society, France ANR, Other; American Board of Internal Medicine, Research Grant; American Heart Association, National Institutes of Health.
Ownership Interest; Yap Therapeutics.
Other Research Support; CSL Limited.
None.

EA.FIS.780: Arrhythmia Research Summit: Preventing and Managing Ventricular Arrhythmias and Sudden Death

DESCRIPTION:

Frontiers in Science: Arrhythmia Research Summit

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-114-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Rachel J Lampert	Honoraria; Medtronic, Research Grant; Amgen, Medtronic, St Jude/Abbott.
Francis E Marchlinski	Honoraria; Boston Scientific, Biotronik, Other; Abbot/ St Jude Medical, Medtonic, Biosense Webster.

Other; Capricor Therapeutics Inc. only for exosomes, Ownership Interest; Capricor Therapeutics Inc. only for exosomes, Stock Shareholder; Capricor Therapeutics Inc. only for exosomes.
None.

EA.FIS.781: Arrhythmia Research Summit: Novel Innovations in Arrhythmia Diagnosis and Management

DESCRIPTION:

Frontiers in Science: Arrhythmia Research Summit

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/facult	ty have declared infancial interest(s) and/or anniations.
Vivek Y Reddy	Honoraria; Boston Scientific, Research Grant; Biosense-Webster,
	Abbott, Stock Shareholder; Ablacon, Acutus Medical, Affera.
J Kevin Donahue	Other; Rithim Biologics.
Hugh G Calkins	Honoraria; Biosense, Boston Scientific, Abbott Medical,
	Boehringer Ingelheim, Atricure, Medtronic.
Bruce L Wilkoff	Other; Abbott, Medtronic, Philips.
Amin Al-ahmad	Honoraria; Boston Scientific, Abbott, Biosense Webster,
	Speaker/Speaker's Bureau; Medtronic .
Stacey Rentschler	None.
Elaine Wan	None

EA.HL.60: A Kaleidoscope of Viewpoints: Hybrid EP Procedures

DESCRIPTION:

This cardiovascular seminar is meant to be multidisciplinary, including professionals such as electrophysiologists, cardiac anesthesiologists, CT surgeons and Heart Failure specialists. Hybrid EP procedures (such as convergent AF ablation and epicardial VT ablation) can be discussed through different perspectives.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.50 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Agnieszka Trzcinka	None.
Rita A Jermyn	Speaker/Speaker's Bureau; Novartis, Abbott.
Melissa Robinson	Honoraria; Medtronic, Sana, Abbott.

EA.HL.430: Code Blue: Arrhythmia Management in the Critical Care Setting

DESCRIPTION:

This session will provide education on new and emerging therapies for the management of arrhythmias in the critical and acute care environments, including the current controversies in management. This session is proposed and sponsored by both the Acute Care Committee and the ECG and Arrhythmia Committee.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM Physicians should claim only the credit commensurate with the extent

Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-115-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Abdulla A Damluji	None.
Janice Y Chyou	Honoraria; Medtronic.
Babak Nazer	Research Grant; Biosense-Webster International, Abbott, Inc

Jose A Joglar

None.

EA.HL.461: Challenging Atrial Arrhythmias in the EP Lab? Decoding the Complex Circuits

DESCRIPTION:

This is a case-based discussion. Speakers bring tough atrial arrhythmia cases from their EP lab, and discuss how they identified the circuits and successfully ablated them.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.50 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Arun Mahankali	None.
Sridhar	
Jodi Zilinski	Honoraria; Abbott Laboratories, Other; Medtronic.
Ann C Garlitski	Other; UpToDate.

EA.JS.785: 2020 Updates in Arrhythmia Detection and Management from the Experts - AHA Joint Session with Heart Rhythm Society

DESCRIPTION:

AHA Joint Session with Heart Rhythm Society

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-150-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Wendy S Tzou	Honoraria; Biotronik, BioSig, Boston Scientific, Medtronic, Abbott, Biosense Webster.
Vivek Y Reddy	Honoraria; Boston Scientific, Research Grant; Biosense-Webster, Abbott, Stock Shareholder; Ablacon, Acutus Medical, Affera.

Mintu Turakhia	Honoraria; Medtronic, Abbott, Other; Pfizer, Johnson and Johnson, Ownership Interest; Forward, Research Grant; Apple, Janssen, Bayer, AHA, Bristol Myers Squibb.
Elaine Hylek	Honoraria; Medtronic, Roche, Abbott, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Research Grant; Janssen.
Andrew Krahn	Honoraria; Medtronic.

EA.ME.578: Atrial Fibrillation: Time for a Paradigm Shift in Management

DESCRIPTION:

This session will navigate through the paradigm changes that have taken place in AF management over the past decades, including updates and novel treatment approaches.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement – Pharmacists ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-116-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Rakesh	Honoraria; Abbott Medical, Zoll Medical, Research Grant; Boston
Gopinathannair	Scientific, Speaker/Speaker's Bureau; Pfizer.

Prashanthan Sanders	Other; Abbott Medical, Medtronic, CathRx, Pacemate, Boston Scientific, Research Grant; Microport, Abbott Medical, Medtronic, Boston Scientific.
Jennifer Wright Jonathan W Dukes	Speaker/Speaker's Bureau; Abbot. Other Research Support; Boston Scientific, Speaker/Speaker's Bureau; Medtronic, Biotronik, Biosense Webster.
Christine M Albert Andrea M Russo	Research Grant; St. Jude Medical, Abbott, Roche. Other; Boehringer Ingelheim, Boston Scientific, Apple, Boston Scientific, Up-To-Date.
Kim-Lien Nguyen	None.

EP.CVS.502: Addressing Personal and Professional Wellness in Academic Medicine

DESCRIPTION:

Burnout is increasingly rampant in academic medicine and is experienced by most at one or multiple points in their career. Although burnout is common among both physician-scientists (MDs or MD/PhDs) and research scientists (PhD), the experiences may be different for these career trajectories given the unique institutional expectations, professional roles, and benchmarks for success for MDs versus PhDs. This session will aim to facilitate discussions regarding burnout among research scientists and physician-scientists within cardiovascular academic medicine.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

David Edmund Anstey	None.
Nour Makarem	Research Grant; National Heart, Lung, and Blood Institute K99 HL148511.
Monik C Jimenez	Employment; Bohn Epidemiology, Research Grant; NIH.

Kathryn M Rexrode	Expert Witness; Sibley Austin (Law Firm).
Joshua Jonathan	None.
Joseph	
Shakira F Suglia	None.

EP.CVS.606: Beyond Biomarkers: Inflammation and CVD Across the Translational Spectrum

DESCRIPTION:

This is a set of rapid-fire presentations that cover the translational spectrum of inflammation in CVD, diving into the underlying pathophysiology and its relevance for epidemiology and clinical interventions.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Claudia Monaco	None.
Paul M Ridker	Honoraria; Novartis, J&J, Merck, Sanofi, Amarin, Peter Munk Toronto, Pfizer, Baim Institute, Cleveland Clinic, Civi Biopharm, Iqvia, Corvidia, Research Grant; Kowa, Novartis, NHLBI, Amarin.
Antonio Abbate	Honoraria; Merck, Serpin Pharma, GSK, Novo Nordisk, Cromos Pharma, Research Grant; Swedish Orphan Biovitrum, Olatec, Novartis.

Peter Libby	Other; Novartis, Amgen, AstraZeneca, Esperion Therapeutics, Novo Nordisk, Kowa Pharmaceutical, Novartis, Pfizer, Sanofi- Regeneron, XBiotech, Inc., Corvidia Therapeutics, DalCor Pharmaceuticals, Merck, Olatec Therapeutics, Medimmune, Novartis, Baim Institute, Kancera.
Matthew J. Feinstein	None.
Rekha Mankad	None.
Russell P Tracy	None.
EP.CVS.610: Emerging Risk Factors: Causation or Correlation?

DESCRIPTION:

Speakers will present on emerging CVD risk factors and audience members will vote (with their body or ARS) on whether they are causal or correlates of other risk factors.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Andreas Daiber	None.
Brian Joyce	None.
Pradeep Natarajan	Other; Apple, Research Grant; Amgen, Boston Scientific, Apple.
John T Wilkins	None.

EP.CVS.614: Predicting and Preventing Cardiovascular Disease in Patients with Diabetes

DESCRIPTION:

Session on predicting and preventing cardiovascular disease in patients with diabetes

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Ambarish Pandey	None.
Jaime Almandoz	None.
Justin B Echouffo-	None.
Tcheugui	
Kershaw Patel	None.
Maria Odette Gore	None.

EP.HL.729: 2020 Vision for 2050: Predicting the Future of Cardiovascular Health and Medicine

DESCRIPTION:

This is a set of rapid-fire TED-style talks which will be focused on major conclusions/points which the speakers then expound upon.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-117-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Sekar Kathiresan - Employment; Verve Therapeutics, Other; Color Genomics Inc., Medgenome, Corvidia, Pfizer, Blackstone, Foresite Labs, Regeneron Genetics Center, Ownership Interest; Catabasis, Maze Therapeutics, San Therapeutics, Verve Therapeutics. Michael V McConnell - Employment; Google/Alphabet, Stock Shareholder; Google/Alphabet. Holly C Gooding - Honoraria; Havard Macy Institute, Research Grant; NHLBI. Kiarri N Kershaw - None. Vasan S Ramachandran - None.

FS.01: Cardiac Procedural Innovation for Special Patient Groups

DESCRIPTION:

A unique combination of arrhythmia and interventional cardiovascular treatment innovations for improving patient care delivery.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date: 11/17/2013 Joint Accreditation Term: 11/18/2020 - 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Demetris Yannopoulos,

Jason Bartos, Ganesh Raveendran, Emily Walser, John Connett, THOMAS Murray, Marinos Kosmopoulos, U Rajat Kalra, Minneapolis, MN; Ranjit John, Andrew Shaffer, RJ FRASCONE, Keith Wesley, Marc Conterato, George Sopko, Michelle H Biros, Tom P Aufderheide D. Yannopoulos: Research Grant; national institute of health the ARREST trial ., Helmsley Charitable Trust. J. Bartos: None. G. Raveendran: None. J. Connett: None. T. Murray: None. M. Kosmopoulos: None. R. Kalra: None. R. John: Research Grant; Abbott Medical. Honoraria; Abbott Medical. Research Grant; Medtronic. Honoraria; Medtronic. K. Wesley: None. M.H. Biros: None. T.P. Aufderheide: Research Grant; NINDS, NHLBI.

James V Freeman,

Angela Higgins, Yongfei Wang, Chengan Du, Usama Daimee, Karl E Minges, Daniel Friedman, Matthew J Price, Paul D Varosy, Frederick A Masoudi, Jeptha P Curtis J.V. Freeman: Honoraria; Janssen Pharmaceuticals, Medtronic, Boston Scientific, Biosense Webster. Other Research Support; American College of Cardiology. Y. Wang: None. C. Du: None. K.E. Minges: Other Research Support; American College of Cardiology. M.J. Price: Honoraria; Abbott Vascular, Boston Scientific, Medtronic, W.L. Gore. P.D. Varosy: None. F.A. Masoudi: Other; American College of Cardiology. Honoraria; Massachusetts Medical Society (JournalWatch Cardiology), UpToDate, TurningPoint Health Solutions. J.P. Curtis: Employment; ACC. Other Research Support; ACC. CMS. Stock Shareholder; Medtronic.

Sripal Bangalore, G B

Mancini, Jonathon Leipsic, Matthew J Budoff, Ylfan Xu, Rebecca Anthopolos, Aeshita Dwivedi, John Spertus, Philip Jones, Daniel B Mark, Cameron Hague, James K Min, Harmony Reynolds, Ahmed Elghamaz, Rajesh Nair, Kreton Mavromatis, Gilbert Gosselin, Subhash Banerjee, Hristo Pejkov, Steven Lindsay, David O Williams, Gregg W Stone, Sean M. O'Brien, Judith S Hochman, David J Maron

Duk-hyun Kang, Sung-ji Park, Seung-ah Lee, Sahmin Lee, Dae-hee Kim, Geu-Ru Hong, Jong-Min Song, Myeong-Ki Hong, Seung Woo Park,Seung-jung Park,

Marco A Zenati, Deepak

L Bhatt, Eileen Stock,Brack Hattler II, Todd Wagner, Ellen Dematt, Faisal Bakaeen, Kousick Biswas, Annette Phillips, Ronnie Ramadan, Elaine E Tseng

S. Bangalore: Research Grant; Abbott Vascular. Honoraria; Biotronik, Pfizer, Amgen, Abbott Vascular. G.B. Mancini: Other Research Support; Merck. Honoraria; AstraZeneca, Novo Nordisk, Boeringher Ingelheim, Bayer. Speaker/Speaker's Bureau; Amgen, Sanofi. Other; Esperion, Novartis, Servier, HLS Therapeutics. J. Leipsic: Stock Shareholder; Circle CVI, HeartFlow. Other; Edwards LifeSciences, Medtronic, Abbott. Honoraria; MVRX. M.J. Budoff: Research Grant; General electric, Amarin. R. Anthopolos: None. J. Spertus: Honoraria; AstraZeneca, Bayer, Novartis, Janssen, Cytokinetics, Myokardia, United Healthcare. Other; Blue Cross Blue Shield of Kansas City. Ownership Interest; Health Outcomes Sciences, Copyrights to KCCQ, SAQ and PAQ. P. Jones: None. D.B. Mark: Research Grant; Merck, Oxygen Therapeutics, HeartFlow. Other; CeleCor, NovoNordisk. J.K. Min: Employment; Cleerly, Inc. Ownership Interest; Cleerly, Inc. Other; Arineta. H. Reynolds: None. K. Mavromatis: None. G. Gosselin: None. S. Banerjee: Honoraria; Medtronic, Livmor. Research Grant; Boston Scientific Corporation, Chiesi. S. Lindsay: None. D.O. Williams: None. G.W. Stone: Other; Shockwave, Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix. Speaker/Speaker's Bureau; Cook. J.S. Hochman: Employment; NYUSOM. Other Research Support; AstraZenecaPharmaceuticals, LP, Arbor Pharmaceuticals, LLC. Other; Amgen, Inc. Research Grant; NIH/NHLBI grant support for ISCHEMIA Trial. Other; Abbott Vascular, Medtronic, Inc; St Jude Medical, Inc, Volcano Corp, Merck Sharp & Dohme Corp, Omron Healthcare, Inc. D.J. Maron: Research Grant; National Heart, Lung, and Blood Institute.

D. Kang: None. S. Park: None. S. Lee: None. S. Lee: None. D. Kim: None. G. Hong: None. J. Song: None. M. Hong: None. S. Park: None. S. Park: None.

M.A. Zenati: None. D.L. Bhatt: Research Grant; Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laborato. E. Stock: None. B. Hattler: None. E. Dematt: None. F. Bakaeen: None. K. Biswas: None. A. Phillips: None. R. Ramadan: None. E.E. Tseng: Research Grant; NIH. Other; Cryolife, Inc, UCSF, ReValve Med, Inc, Editor, Journal of Heart Valve Disease.

Paul C Cremer, Calvin	P.C. Cremer: None. C. Sheng: None. J. Hernandez-Montfort: None. T.
Sheng, Debasis Sahoo,	Wang: None. O. Abou Hassan: None. D. Brennan: None. D. Culver:
Siddharth Dugar, Robier	None. A. Duggal: None. A.M. Lincoff: Research Grant; Astra Zeneca,
Aguillon-Prada, Jaime	Esperion, AbbVie, CSL, Novartis. Honoraria; Eli Lilly, Novo Nordisk.
Hernandez-Montfort,	S.E. Nissen: Research Grant; Astra Zeneca, Amgen, Pfizer, Novartis,
David Wolinsky, Tom Kai	Esperion, Eli Lilly, AbbVie, MyoKardia, Silence Therapeutics,
Ming Wang, Ossama	Medtronic. V. Menon: None.
Abou Hassan, Danielle	
Brennan, Daniel Culver,	
Prabalini Rajendram,	
Abhijit Duggal, A	
Michael M Lincoff,	
Steven E Nissen, Venu	
Menon,	

Manesh R Patel

Research Grant; Astra Zeneca, Bayer, Janssen, Procyrion Inc, Heartflow, Other; Bayer, Janssen, Mytonomy.

FS.02: SGLT2i for non-Diabetic Indications: Updates from Mega-Trials and Mechanistic Insights

DESCRIPTION:

Scientific break throughs will be presented which no clinician should miss! Cardiovascular, renal and metabolic therapies having the potential to improve patient function in those with chronic cardiovascular disease profiles.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

David Cherney, Bernard Charbonnel, Francesco Cosentino, Richard Pratley, Samuel Dagogo-Jack, Weichung J Shih, Darren K McGuire, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P. Cannon; on behalf of the VERTIS CV Investigators

D. Cherney: Other; Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, AstraZeneca, Merck & Co Inc., Novo Nordisk, Prometic, Bristol-Myers Squibb, Mitsubishi-Tanabe, MAZE, Bayer. B. Charbonnel: Honoraria; AstraZeneca, Merck, MundiPharma, Sanofi, NovoNordisk. F. Cosentino: Research Grant; Swedish Research Council, Swedish Heart and Lung Foundation, King Gustav V and Queen Victoria Foundation. Speaker/Speaker's Bureau; AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Mundipharma, Pfizer, Novo Nordisk. R. Pratley: Other; Hanmi Pharmaceutical, Janssen Research & Development LLC, Merck Sharp & Dohme Corp, Novo Nordisk Inc, Pfizer Inc., Poxel SA, Sanofi US, Scohia Pharma Inc., Sun Pharmaceutical Industries Ltd. S. Dagogo-Jack: Honoraria; Merck, Sanofi, Janssen, AstraZeneca. Stock Shareholder; Jana Care, Inc.Aerami Theapeutics. W.J. Shih: None. D.K. McGuire: Other Research Support; AstraZeneca, Sanofi, Boehringer Ingelheim, Merck & Company, Pfizer, Novo Nordisk, Eisai Inc, Esperion, Lilly USA, GlaxoSmith Kline, Janssen, Lexicon. Honoraria; Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Metavant, Applied Therapeutics, Sanofi, AstraZeneca. Other Research Support; Akebia, AbbVie, Eidos, Arena, Dynavax, Otsuka, CSL Behring. Honoraria; GlaxoSmithKline, Afimmune. R. Frederich: Employment; Pfizer Inc. Stock Shareholder; Pfizer Inc, Bristol-Myers Squibb. M. Maldonado: Employment; MSD. J. Liu: Employment; Merck. A. Pong: Employment; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Other; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. C. Liu: Employment; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. C.P. Cannon: Research Grant; Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Pfizer. Honoraria; Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer Rhoshan, Sanofi.

John J V McMurray,

David C Wheeler, Bergur V Stefansson, Ricardo Correa Rotter, Glenn M Chertow, Tom Greene, Fan Fan Hou, Magnus B Lindberg, Peter Rossing, David Sjostrom, Robert D Toto, Anna Maria Langkilde, Hiddo JI Lambers Heerspink, on behalf of the DAPA-CKD Committees and Investigators

J.J. McMurray: Other; Bayer, Cardiorentis, Amgen, Oxford University/Bayer, Theracos, Abbvie, Dalcor, Pfizer, Merck, Glaxo Smith Kline (GSK), Bristol Myers Squibb (BMS), Vifor-Fresenius, Kidney Research UK (KRUK), Novartis, AstraZeneca. D.C. Wheeler: Other; Amgen, AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Mitsubishi, Mundipharma, Napp, Ono Pharma, Tricida, Vifor Fresenius. Speaker/Speaker's Bureau; Amgen, Astellas, Boehringer Ingelhiem, Astellas, Napp, Merck Sharpe and Dohme, Mundipharma,. B.V. Stefansson: Employment; AstraZeneca. R. Correa Rotter: Other Research Support; AstraZeneca. Research Grant; Abbvie, GSK, NovoNordisk. Other Research Support; Boheringer Ingelheim. Speaker/Speaker's Bureau; Medtronic, Amgen, Takeda. G.M. Chertow: Other; Akebia, Amgen, AstraZeneca, Baxter, Cricket Health, Durect, Gilead, Reata, Sanfit, Vertex. Stock Shareholder; Ardelyx, Outset. T. Greene: Other; Janssen, Durect, Astrazeneca, CSL, Boehringer-Ingleheim and Pfizer. F. Hou: Other; AstraZeneca, AbbVie. M.B. Lindberg: None. P. Rossing: Other; Bayer, Astellas, Astra Zeneca, Boehringer ingelheim, Novo Nordisk, Gilead, Mundipharma, Merck, Vifor, Sanofi. D. Sjostrom: Employment; AstraZeneca. Stock Shareholder; AstraZeneca. R.D. Toto: Other; Amgen, Boehringer-Ingelheim, Bayer, Astra-Zeneca, Quest Diagnostics, Reata, Relypsa, Otsuka, Medscape. A. Langkilde: Employment; Stock Shareholder; AstraZeneca. H.J. Lambers Heerspink: Research Grant; AstraZeneca. Research Grant; Abbvie, Boehringer Ingelheim, Janssen. Other; Gilead, merck, Mitsubishi Tanabe, MundiPharma, Chinook, CSL Pharma, Bayer, Retrophin, Novo Nordisk.

Carlos G Santos-Gallego, Ariana P Vargas- Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Farah Atallah-Lajam, Johanna Paola Contreras, Frank Macaluso, Samantha Sartori, Merce Roque, Icilma Fergus, Fernando Sabatel-Perez, Anderly Rodriguez-Cordero, Urooj Zafar, Pedro R. Moreno, Vivian M. Abascal, Icahn Sch of Med at Mount Sinai, New York, NY; Anu Lala, Ronald Tamler, Javier Sanz, Valentin Fuster, Juan J Badimon	A. Garcia-Ropero: None. S. Sartori: None. M. Roque: None. I. Fergus: None. F. Sabatel-Perez: None. P.R. Moreno: Speaker/Speaker's Bureau; Abiomed, Cuquerella medical, Amgen. R. Tamler: None. J. Sanz: None. V. Fuster: None. J.J. Badimon: Research Grant; Boehringer-Ingelheim.
Geu-Ru Hong , Chi Young Shim, Iksung Cho, Jiwon Seo, Jong-Won Ha	G. Hong: None. C. Shim: None. I. Cho: None. J. Ha: None.
Matthew Lee, SUGAR- DM-HF Investigators	Research Grant; Boehringer Ingelheim.
Javed Butler, EMPEROR-Reduced Trial Committees and Investigators	J. Butler: Honoraria; Astra Zeneca, Bayer, Boehringer Ingelheim, Impulse Dynamics, Janssen, Merck, Novartis, Relypsa, Vifor, Abbott, Adrenomed, Amgen, Array, BerlinCures, CVRx, G3 Pharmaceutical, Innolife, LinaNova, Luitpold, Medtronic, NovoNordisk, Relypsa, Roche, Sanofi, V-Wave Limited. Speaker/Speaker's Bureau; Novartis, Janssen, Astra Zeneca, BI/Lilly.

FS.03: Cardiovascular Toolbox: Clots and Claudication

DESCRIPTION:

In this clinical science session the presenters will highlight the latest trial data on anticoagulation for multiple types of cardiovascular diseases which include vascular disease, atrial fibrillation, valve thrombus, and endovascular intervention.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Mary M McDermott,

Bonnie Spring, Lydia A Bazzano, Michael H Crigui, Kathryn Domanchuk, Luigi Ferrucci, Daniel E Forman, Jack Guralnik, Melina R KIBBE, Christiaan Leeuwenburgh, Donald M Lloyd-Jones, Todd Manini, Tamar S Polonsky, Alvito Rego, Brittany Smith, Robert Sufit, Lu Tian, Diane J Treat-jacobson, Dongxue Zhang, Lihui Zhao, W. Jack Rejeski

M.M. McDermott: Other; Helixmith, Hershey Company, Chromadex, ReserveAge, Mars, Art Assist. Research Grant; Regeneron. B. Spring: Other; Actigraph, Apple. L.A. Bazzano: None. M.H. Criqui: None. K. Domanchuk: None. D.E. Forman: None. J. Guralnik: None. M.R. Kibbe: None. C. Leeuwenburgh: None. D.M. Lloyd-Jones: None. T.S. Polonsky: None. A. Rego: None. B. Smith: None. R. Sufit: None. L. Tian: None. D.J. Treatjacobson: Research Grant; NIH. D. Zhang: None. L. Zhao: None. W. Rejeski: None.

Marc P Bonaca,

Sebastian Debus, Manesh R Patel, Mark R Nehler,Sonia Anand, Connie N Hess, Warren Capell, Lihong Diao, Scott D Berkowitz, Eva Muehlhofer, Lloyd P Haskell, Rupert Bauersachs, William R. Hiatt M.P. Bonaca: Honoraria; Amgen, Pfizer, Regeneron, Astrazeneca, Bayer, Janssen, Lexicon, Merck, NovoNordisk. Research Grant; Regeneron, Amgen, Astrazeneca, Audentes, Bayer, BIDMC, BMS, Janssen, Lexicon, Medtronic, Merck, NovoNordisk. S. Debus: Research Grant; Bayer, Janssen, Procyrion Inc, Heartflow. Honoraria; Bayer. Speaker/Speaker's Bureau; Bayer. Other; Bayer. M.R. Patel: Research Grant; Modest; Astra Zeneca, Bayer, Procyrion Inc, Heartflow, Janssen. Other; Significant; Bayer, Janssen, Mytonomy. M.R. Nehler: Research Grant; Bayer, Janssen. Other; CPC Research. S. Anand: Honoraria; Bayer AG. C.N. Hess: Research Grant; Amgen, Merck, Bayer, Janssen. W. Capell: Other; Bayer AG & Janssen Research and Development, LLC. L. Diao: None. S.D. Berkowitz: Employment; Bayer U.S. LLC. E. Muehlhofer: Employment; Bayer AG. L.P. Haskell: Employment; Janssen. R. Bauersachs: Honoraria; Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer.

Manesh R Patel, Sonia

Anand, Rupert Bauersachs, Scott D Berkowitz, Taylor Brackin, Sebastian Debus, Lloyd P Haskell, Connie N Hess, William R. Hiatt, William S Jones, Eva Muehlhofer, Mark R Nehler, Marc P Bonaca M.R. Patel: Research Grant; Modest; Astra Zeneca, Bayer, Procyrion Inc, Heartflow, Janssen. Other; Bayer, Janssen, Mytonomy. S. Anand: Honoraria; Bayer AG. R. Bauersachs: Honoraria; Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer. S.D. Berkowitz: Employment; Bayer U.S. LLC. T. Brackin: None. S. Debus: Research Grant; Bayer. Honoraria; Bayer. Speaker/Speaker's Bureau; Bayer. Other; Bayer. L.P. Haskell: Employment; Janssen. C.N. Hess: Research Grant; Amgen, Merck, Bayer, Janssen. W.S. Jones: Research Grant; Bristol Myers Squibb, Medtronic. Honoraria; Bayer, Janssen Pharmaceuticals. E. Muehlhofer: Employment; Bayer AG. M.R. Nehler: Research Grant; Bayer, Janssen. Other; CPC Research. M.P. Bonaca: Honoraria; Amgen. Astrazeneca, Bayer, Merck, Janssen, Pfizer, Regeneron, NovoNordisk. Research Grant; Significant; Amgen, Astrazeneca, Audentes, Bayer, BIDMC, BMS, Janssen, Lexicon, Medtronic. Merck, NovoNordisk, Regeneron.

Tetsuya Matoba,

Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Masato Nakamura, Katsumi MIYAUCHI, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa T. Matoba: Speaker/Speaker's Bureau; Bayer, MSD. Daiich Sankyo, Astellas, Abbott Vascular. S. Yasuda: None. K. Kaikita: Honoraria; Bayer Yakuhin, Ltd.Daiichi-Sankyo Co., Ltd. Research Grant; Bayer Yakuhin, Ltd.Daiichi-Sankyo Co., Ltd. Novartis Pharma AGSBI Pharma K.K. M. Akao: Speaker/Speaker's Bureau; Bristol-Myers Squibb, Bayer Healthcare, Daiichi-Sankyo. J. Ako: Speaker/Speaker's Bureau; Sanofi, Otsuka, Bristol Meiers, MSD, Eli Lilly, Terumo, Astellas Amgen, Actellion, Boehringer Ingelheim, Daiichi Sankyo, Bayer, Boston Scientific, Edwards Lifesciences, Tanabe Mitsubishi. Honoraria; Pfizer. M. Nakamura: Speaker/Speaker's Bureau; Bayer, Daiichi Sankyo, Bristol-Myers Squibb. K. Miyauchi: None. N. Hagiwara: Speaker/Speaker's Bureau; Bayer Yakuhin, Ltd. Bristol-Myers Squibb K.K., Nippon Boehringer Ingelheim Co,Ltd. Research Grant; Bayer Yakuhin, Ltd., Daiichi Sankyo Company. K. Kimura: Research Grant; Otsuka Pharmaceutical Co., Ltd.Boehringer Ingelheim Japan, Inc. Honoraria; Daiichi Sankyo Company, Limited, AstraZeneca. A. Hirayama: Speaker/Speaker's Bureau; Bayer Pharma Japan, Daiichi-Snakyo Pahrma, Brystol-Myers Squib, Takeda Pharma. K. Matsui: None. H. Ogawa: None.

Mahmoud Abdelnabi,

Yehia Saleh, Ahmed Fareed, Alexander Nossikoff, Ling Wang, Mahmoud Morsi, Nouran Eshak, Ola Abdelkarim, Haitham Badran, Abdallah Almaghraby **M. Abdelnabi**: None. Y. Saleh: None. M. Morsi: None. N. Eshak: None. H. Badran: None. A. Almaghraby: None.

GE.CVS.629: State of the Art: Hypertrophic Cardiomyopathy

DESCRIPTION:

This session highlights the current state of the art for hypertrophic cardiomyopathy (HCM).

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013

Joint Accreditation Term: 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations: Sara Saberi - Honoraria; MyoKardia, Inc..

Perry Elliott - Honoraria; MyoKardia, Pfizer, Alnylam, Sanofi Genzyme, Research Grant; Pfizer. Iacopo Olivotto- Research Grant; Myokardia, Sanofi Genzyme, Shire, Bayer, Menarini International. Christine E Seidman - Other; Burroughs Wellcome Foundation, Maze Therapeutics, Myokardia, Merck, Research Grant; Howard Hughes Medical Institute, NIH. Steve R Ommen - None.

GE.CVS.745: Precision Medicine Science of the Future

DESCRIPTION:

Session on precision medicine science of the future.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-118-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

George A Truskey - None. Jeffrey Anderson - None. Susan Cheng - Other; Zogenix, Research Grant; NIH. Erich Huang - Ownership Interest; kelaHealth, Stratus Medicine, Medblue Data.

GR.CVS.106: Is My Patient Frail and What Do I Do About It? Managing Frail Older Adults with CVD

DESCRIPTION:

Older adults comprise the majority of patients seen in Cardiology and up to half are frail. The management of frail older adults can be complicated by competing priorities. In this session we will address the management of the frail older adult using common clinical scenarios including ACS, HF, and HTN.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular

physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-119-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Adam J Nelson - None. Karen L Furie - None. Karen P Alexander - None. Shadi Yaghi - Other; Medtronic. Quin E Denfeld - Research Grant; NIH/ORWH K12HD043488. Michael Nanna - Other; NIH T-32-HL069749-15. Sarah Goodlin - None.

GR.CVS.249: Overview of Cardiovascular Health Issues Unique to LGBTQ Populations: What We Know and What We Need to Know

DESCRIPTION:

This session will provide an overview of the cardiovascular health issues unique to LGBTQ populations.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Billy A Caceres - None. Carl Streed - None. Tonia Poteat - Research Grant; Viiv Healthcare. Paula Neira - None. Lauren Brittany Beach - Research Grant; National Institutes of Health.

GR.CVS.346: Heart Disease in Women: State-of-the-Art in 2020

DESCRIPTION:

This session will provide an overview of the cardiovascular health issues unique to LGBTQ populations.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.25 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.25 Contact Hours. Universal Program Number: JA0000134-0000-20-151-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Leslie A Leinwand - Other; Edgewise Therapeutics, Inc., Fulcrum Therapeutics, Hiberna, Inc.. Stock Shareholder; MyoKardia, Inc.. Umesh Khot - None.

GR.CVS.376: Am I at Risk?: Cardiovascular Disease Prevention and Treatment in Diverse Populations

DESCRIPTION:

The purpose of this session is to highlight the challenges that are unique to specific racial and ethnic groups in the prevention and treatment of cardiovascular disease both in the US and in Europe.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.50 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Alka M Kanaya - None. Charles Agyemang - None. Alanna A Morris - Research Grant; NIH/NHLBI, Woodruff Foundation .

GR.CVS.446: Cardiovascular Disease Prevention in Older Adults: Reconciling Recommendations with Reality

DESCRIPTION:

This session will explore the risks, benefits, and challenges of implementing cardiovascular disease prevention guidelines and therapies in older adults.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-120-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Michael A Blazing - Honoraria; Espirion.

Cecilia C Low Wang - Employment; University of Colorado School of Medicine, CPC Clinical Research, Other; Clinical Endocrine Institute, Speaker/Speaker's Bureau; Medical Education Resources.

Ariela R Orkaby - Research Grant; Veterans Administration, NIH. William Cushman - None.
GR.CVS.742: Inter-generational Relationship of Mother and Offspring in Heart Disease

DESCRIPTION:

In any pregnancy, there are 2 patients and there are lifelong consequences of poor cardiovascular health during pregnancy for both mother and child.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date: 11/17/2013 Joint Accreditation Term: 11/18/2020 - 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Nanette K Wenger - Other; Department of Defense (DoD), Amarin Pharma, Inc., AstraZeneca, Janssen Pharmaceuticals, Research Grant; AstraZeneca, Boeringer Ingelheim, NHLBI. Holly C Gooding - Honoraria; Havard Macy Institute, Research Grant; NHLBI. Amanda Perak - Research Grant; NHLBI K23 career development award. Allison Cirino - Other; Ambry Genetics.

GR.CVS.812: Cardiovascular Disease in the Latino/Hispanic Community: Challenges and Opportunities

DESCRIPTION:

Session on cardiovascular disease in the Latino/Hispanic community: challenges and opportunities.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013

Joint Accreditation Term: 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Hector O Ventura - None.

Leandro Slipczuk - None.

Mauricio G Cohen - Honoraria; Merit Medical, Abiomed, Zoll, Medtronic, AstraZeneca, Ownership Interest; Accumed Radial Systems.

Jorge R Kizer - Stock Shareholder; Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Merck, Pfizer.

Fatima Rodriguez - Other; HealthPals, NovoNordisk, Janssen, The Medicines Company.

GR.HL.790: 5 Questions about Heart Disease in Women

DESCRIPTION:

Understanding heart disease in women.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013

Joint Accreditation Term: 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Jennifer Lewey - None.

Colin Berry - Other; HeartFlow, Other Research Support; Siemens Healthcare, Research Grant; AstraZeneca, GSK, Novartis, Speaker/Speaker's Bureau; Abbott Vascular, Menarini. John J McMurray - Other; Bayer, Cardiorentis, Amgen, Oxford

University/Bayer, Theracos, Abbvie, Dalcor, Pfizer, Merck, Novartis, Glaxo Smith Kline (GSK), Bristol Myers Squibb (BMS), Vifor-Fresenius, Kidney Research UK (KRUK), AstraZeneca. Tochi M Okwuosa - None.

HF.CVS.635: Controversies in the Management of Cardiac Decompensation: A Mini Debate Series

DESCRIPTION:

This session will discuss (1) spectrum and prevalence of cardiogenic shock subtypes, (2) Approaches to management and temporary mechanical support selection, and (3) the interdisciplinary approach to cardiogenic shock involving interventional, heart failure, cardiac surgery, critical care.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations: Holger Thiele - None.

Shelley Hall - Other; Abbott, Abiomed, CareDx, Evaheart, Syncardia, Speaker/Speaker's Bureau; Novartis.

Rebecca Cogswell - Other; Medtronic, Speaker/Speaker's Bureau; Abbott , Stock Shareholder; Medronic- Husband's employment .

Mark H Drazner- None.

Lee R Goldberg - Honoraria; Abbott, Other; Respircardia.

Graham C Wong - Honoraria; HLS Therapeutics, Speaker/Speaker's Bureau; Novartis.

Demetris Yannopoulos - Research Grant; national institute of health the ARREST trial ., Helmsley Charitable Trust.

David A Morrow - Other; InCarda Therapeutics, Merck & Co, Roche Diagnostics, Novartis, Research Grant; Abbott laboratories, Roche Diagnostics, Siemens, Amgen, Anthos, AstraZeneca, Daiichi Sankyo, Eisai, Johnson & Johnson, Merck & Co, Novartis, Pfizer.

Cindy L Grines - Other; Abiomed, Philips. Amish N Raval - Other Research Support; Biocardia Inc., Biosense Webster, Ownership Interest; Cellular Logistics Inc. . Sofia Carolina Masri - None.

HF.CVS.646: Acute Decompensated Heart Failure: Critical Issues For The Clinician

DESCRIPTION:

The critical issues focus on trajectories of heart failure, cardiorenal disease, the transitional continuum of care delivery. A probing debate will also take place to examine the pros and cons of the role of the cardiologist having heart failure expertise in caring for these patients.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Howard J Eisen - None.

Jennifer T Thibodeau - None.

Kevin Damman - Research Grant; Boehringer Ingelheim, Speaker/Speaker's Bureau; Abbott. Khadijah Breathett - Research Grant; National Institute of Health, University of Arizona, Sarver Heart Center, University of Arizona, Women As One.

Eldrin F Lewis - Other; Merck, Novartis, Dal-Cor, Research Grant; NHLBI, Sanofi, Novartis, Merck. Alpesh N Amin - Honoraria; Medtronic, Pfizer, BMS, Portola, Astra Zeneca.

Omaima Ali - None.

Steven Hollenberg - None.

HF.CVS.651: Emerging Issues in LVAD and Transplant

DESCRIPTION:

This session is focused on the management of patients who need mechanical circulatory support devices, heart transplantation, and management of donors.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date: 11/17/2013 Joint Accreditation Term: 11/18/2020 - 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Shelley Hall - Other; Abbott, Abiomed, CareDx, Evaheart, Syncardia, Speaker/Speaker's Bureau; Novartis.

Ranjit John - Honoraria; Abbott Medical, Medtronic, Research Grant; Abbott Medical, Medtronic. Peter Macdonald - Honoraria; Astra Zeneca, Research Grant; Novartis, Servier, Speaker/Speaker's Bureau; Novartis, Actelion.

Robert Dowling - None.

Stephen Large - None.

HF.CVS.667: Inflammation and Heart Failure: Adding Fuel to the Fire?

DESCRIPTION:

Learning objectives: - Understand signaling mechanisms that lead to activation of innate and adaptive immune cells in HF - Review clinical evidence of inflammation contributing to HF development - Examine existing clinical studies targeting inflammation in HF, both in cardio-oncology as a case example, and among the broader HF population.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular

physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-122-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Neal K Lakdawala - Other; Myokardia, Array Biopharma, Pfizer, Sarepta Therapeutics. Leo Buckley - Research Grant; Akcea Therapeutics. Douglas L Mann - Other; LivaNova, BMS, MyoKardia, Tenaya. Pilar Alcaide - None.

HF.CVS.708: Failure is Not an Option: New Targets, New Opportunities

DESCRIPTION:

This session describes the newest pharmacologic advancements in heart failure management. It will address how to manage polypharmacy, decide on optimal next step for disease management with use of biomarkers and patient characteristics to determine order of meds, and highlight recent developments in the newest classes of GDMT for heart failure.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular

physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation Term:
 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-123-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Eileen M Hsich - None.

Carolyn Lam - Honoraria; Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diag, Ownership Interest; eKo.ai, Research Grant; Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca.

Nasrien E. Ibrahim - Honoraria; Novartis, Roche.

John J McMurray - Other; Bayer, Cardiorentis, Amgen, Oxford

University/Bayer, Theracos, Abbvie, Dalcor, Pfizer, Merck, Bristol Myers Squibb (BMS), Vifor-Fresenius, Kidney Research UK (KRUK), Novartis, Glaxo Smith Kline (GSK), AstraZeneca.

Eldrin F Lewis - Other; Merck, Novartis, Dal-Cor, Research Grant; NHLBI, Sanofi, Novartis, Merck. Alanna A Morris - Research Grant; NIH/NHLBI, Woodruff Foundation.

Marc A Pfeffer - Honoraria; AstraZeneca, Corvidia, GlaxoSmithKline, Jazz, MyoKardia, Novartis, Roche, Sanofi and Servier. Other; DalCor, Novo Nordisk. Research Grant; Novartis. Ownership Interest; DalCor.

Nosheen Reza - None.

HF.EC.636: Hemodynamics in Heart Failure with a Case Based Focus

DESCRIPTION:

Presentation on interesting, hemodynamic cases - including visuals like tracings or images.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013

Joint Accreditation Term: 11/18/2020 – 11/17/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Farhan Raza - None.

Jae K Oh - None.

Jeroen J Bax- Research Grant; Biotronik, Medtronic, Edwards, General Electric, Boston Scientific, Speaker/Speaker's Bureau; Abbott Vascular, Boehringer Ingelheim. Jerry Estep - Other; Getinge, Abbott.

HF.JS.784: Approaches to Improving Clinical Care - AHA Joint Session with Chinese Society of Cardiology

DESCRIPTION:

AHA Joint Session with Chinese Society of Cardiology

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

L Newby - Honoraria; Bristol-Myers Squibb, Quidel, Roche Diagnostics, Ortho-Clinical Diagnostics, NIH/NHLBI, Research Grant; Boehringer Ingelheim, PCORI, Amylin, NIH/NIA.

James A De Lemos - Honoraria; Amgen, Regeneron, Novo Nordisc, Janssen, Quidel Cardiovascular, Eli Lilly, Ortho Clinical Diagnostics, Siemen's Diagnostic, Research Grant; Roche Diagnostics, Abbott Diagnostics.

Biykem Bozkurt - Honoraria; Bristol Myers Squibb, scPharmaceuticals, Inc , Baxter Health Care Corporation, Sanofi Aventis Pharmaceuticals , Relypsa, Other; Respicardia Registry , ABBOTT VASCULAR, Liva Nova.

Yue Li - None.

HF.ME.703: The Very Hottest Topics in Heart Failure for All Cardiologists

DESCRIPTION:

Talks focusing on the very latest topics of interest to all subspeciality and general cardiologists.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Ileana L Pina - None.
Michelle M Kittleson- None.
Randall Starling - Other; Novartis, Research Grant; Corvia , Amgen, NIH.
Ravi Dhingra - Other; Novartis, LivaNova, Ironwood.
Rudolf A De Boer - Research Grant; AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk, Roche, Speaker/Speaker's Bureau; Abbott, AstraZeneca, Novartis, Roche.
Paul A Grayburn - Honoraria; Abbott Vascular, Edwards Lifesciences, Research Grant; Abbott Vascular , Edwards Lifesciences, Medtronic, Boston Scientific, Neochord, W.L. Gore, Cardiovalve. Carolyn Ho - Honoraria; Ambry, Novartis, MyoKardia, Inc.

Biykem Bozkurt - Honoraria; Bristol Myers Squibb, scPharmaceuticals, Inc , Baxter Health Care Corporation, Sanofi Aventis Pharmaceuticals , Relypsa, Other; Respicardia Registry, ABBOTT VASCULAR, Liva Nova.

HY.CVS.102: Novel Anti-Diabetic Agents: A Tidal Wave of Change in the Cardiovascular Care of Patients with CKD

DESCRIPTION:

The field of cardio-nephrology has recently witnessed data from several landmark trials that impact the combination of diabetes and cardio-kidney disease. Multiple new agents that have been developed for the treatment of diabetes have shown major reduction in cardio-kidney morbidity and related mortality, particularly the sodium glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. Additionally, there is a role for the use of the SGLT2 inhibitors in patients with heart failure with reduced ejection fraction, even in the absence of diabetes. Several ongoing trials in this sphere are expected to present new data in 2020-2021. This makes a symposium summarizing the advances in cardio-kidney-metabolic syndrome and methodologies to best translate these data into clinical practice both timely and highly impactful. We anticipate this will generate interest across several specialties that interlink in the care of this high impact sub-specialty. This information is also relevant across several health care backgrounds including clinicians (cardiologists, nephrologists, endocrinologists), scientists (vascular biology, kidney physiology), advanced care practitioners, nurses, and other health care professionals caring for patients with cardio-kidney metabolic disease. Finally, this symposium aligns with the recently announced Kidney Health Initiative by executive order of the president of the United States to reduce CKD burden aggressively, for which the AHA is a strong supporter and collaborator.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology. Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-124-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Mark E Molitch: Honoraria; Merck, Pfizer, Research Grant; Chiasma, Novartis, Strongbridge. Katherine R Tuttle: Honoraria; Bayer, Other; Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio, Novo Nordisk. Peter A McCullough: None.

HY.CVS.130: Circadian Influences on CVD Risk and Drug Therapy

DESCRIPTION:

Modern societies are characterized by artificial light at night, ad libitum access to energy dense foods, and chronic sleep disruption - all of which lead to disrupted circadian rhythms. Circadian disruptions are associated with chronic CV diseases including hypertension, obesity, and cardiac arrhythmias. Inflammation plays an important role in CV disease and the immune system is also subject to circadian-dependent influences. More work is needed to understand the interplay of circadian rhythms, diet, and inflammation in promoting CV disease. The purpose of this session is to highlight and call for additional research in these areas.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-125-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Jennifer S Pollock - None.

Michelle L Gumz - None.

Tami A Martino - Research Grant; Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research.

Sumanth D Prabhu - Other; Sanofi/Genzyme.

Filip K Swirski -Other; Verseau Therapeutics.

HY.CVS.151: Salt-Sensitive Hypertension: What is New?

DESCRIPTION:

Dietary components, including sodium and potassium, interact with the gut microbiota in the regulation of blood pressure and pathogenesis of salt-sensitive hypertension. However, there are no convenient tools for the diagnosis of salt sensitivity of blood pressure, independent of hypertension. The diagnosis of salt sensitivity in normotensives is important since 18% of Americans have normal blood pressure and salt sensitivity which are associated with the same mortality and morbidity as in hypertension. Major strides are being made in developing urine-based tests for these conditions.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias.

Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-126-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Francine Marques - None.

Kathryn Sandberg - None. Lawrence J Appel - Honoraria; Wolters Kluwer (UpToDate). Robin A. Felder - None. Shannon L Lennon - None. Tanika N Kelly - None.

HY.CVS.193: Cardiorenal or Renocardiac Syndrome? Perils, Pitfalls and Progress

DESCRIPTION:

This session involves unraveling the often confusing cardiorenal etiologies and addresses new therapeutic approaches and challenges in this evolving field. The first talk attempts to dissect the clinical syndromes encompassed in "cardiorenal syndrome." Decongestion often comes at the expense of worsening renal function but newer data challenge that increased creatinine engenders poor outcomes. An apparent counterintuitive approach to acute HF is sodium loading; recent data and supporting mechanisms will be reviewed. Optimal GDMT is often sidelined due to concerns of electrolyte imbalance and azotemia in patients with renal disease, this talk discusses the challenges of GDMT in this populations and poor outcomes when therapy is witheld. Finally, determining when a kidney-heart transplant is needed is a difficult task and this talk seeks to explore how to optimally work patients up for combined solid-organ transplant needs.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-127-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.
The following authors/faculty have declared financial interest(s) and/or affiliations: Michelle M Kittleson - None.

Shweta Bansal - Honoraria; UpToDate, Other; Osprey Medical, Speaker/Speaker's Bureau; Home Therapy Institute.

Janani Rangaswami - Other; Procyrion Inc, Rockwell Medical, Speaker/Speaker's Bureau; Abbott. Jeffrey M Testani - Honoraria; Bayer, BMS, Boehiringer, Megentamed, Novartis, Windtree therapeutics, Cardionomic, Sequana, Reprieve medical, FIRE1, Gore, AZ, Research Grant; 3ivelabs, BMS, Boehiringer, Otsuka, Sequana, Sanofi, Sanofi, Abbott.

HY.CVS.538: Extracelluilar Vesicles in Cardiovascular and Renal Diseases

DESCRIPTION:

Extracellular vesicles is an emerging topic in cardiovascular and renal disease.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Elena Aikawa - None. Alfonso Eirin - None. Zhongjie Sun - None.

HY.CVS.628: Hypertension Management in Patients with Complex Comorbidities

DESCRIPTION:

Patients with complex medical conditions have needs that are often not adequately addressed by general hypertension guidelines. This session will describe five chronic conditions that require specialized drug therapy, and clinical considerations including varying intensity of attempting achievement of blood pressure goals.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-128-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Eugene Storozynsky - None. Himabindu Vidula - Research Grant; Abbott. Angela L Brown - Research Grant; Medtronic. Shannon Finks - None.

HY.CVS.632: Improving Treatment Adherence in Hypertension

DESCRIPTION:

Hypertension often appears to be resistant to treatment, but non-adherence to medications is often the cause. This session will discuss best practices to prevent, detect, and improve treatment adherence in hypertension.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-129-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Joseph E Ebinger - None. Mohammed Siddiqui - None. Niteesh K Choudhry - None. Suzanne Oparil - Other; Pfizer, Inc, ROX Medical, Inc, CinCor, Research Grant; Bayer, Idorsia Pharmaceuticals, Ltd., Novartis. James M Luther - Other; Catalys Pacific. Elizabeth J Phillips - Research Grant; NIH. Swapnil Hiremath - None.

HY.CVS.656: Managing Lifespan CVD Risk in Women With Hypertensive Disorders of Pregnancy

DESCRIPTION:

This session will highlight the inordinate lifespan CVD risk experienced by women with any prior hypertensive disorder of pregnancy, especially early (before 34 weeks) pre-eclampsia. The strikingly high risk of persistent, early onset of hypertension will be discussed as will the current guidelines for the surveillance and treatment of these women.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.50 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.50 Contact Hours. Universal Program Number: JA0000134-0000-20-152-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Abbi D Lane-Cordova - None. Heather Boyd - None.

HY.CVS.775: Target BP: Have We Moved the Needle on the Nation's Blood Pressure? - A Discussion on the AHA, AMA, CDC, and NIH on the State of U.S. Hypertension Control Efforts

DESCRIPTION:

Each organization will present a brief summary of their efforts and outcomes from the past 3 year. The panel will discuss evidence of improvement, ongoing gaps and challenges, and priority strategies for escalating and sustaining the attention of the public, health professionals, health care institutions, and policy on hypertension control.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-130-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Betsy Thompson - None. David C Goff Jr. - None. Michael K Rakotz - None. Sandra J Taler - None.

IM.CVS.385: Ischemia After ISCHEMIA: CT vs. Stress Testing

DESCRIPTION:

The usage of Coronary CT imaging in patients with angina has been significantly growing over the last decade. Specially, post presentation of landmark ISCHEMIA trial, the medical community is questioning the role of functional stress testing as compared to anatomical evaluation by coronary CTA. There has also been marked interest in role of CAC in symptomatic patients.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Arthur E Stillman - None. Niti R Aggarwal - None. Parham Eshtehardi - None. Sharmila Dorbala - Honoraria; GE, AAA, Pfizer, Research Grant; GE, Pfizer. Pamela K Woodard - Other; Medtronic, Other Research Support; Siemens Medical Solutions, Research Grant; Roche. Renee P. Bullock-Palmer - None.

IM.CVS.619: Imaging of the Thoracic Aorta: Before and After (Surgery)

DESCRIPTION:

The usage of Coronary CT imaging in patients with angina has been significantly growing over the last decade. Specially, post presentation of landmark ISCHEMIA trial, the medical community is questioning the role of functional stress testing as compared to anatomical evaluation by coronary CTA. There has also been marked interest in role of CAC in symptomatic patients.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Daniel Ocazionez - None. Sandeep S. Hedgire - Employment; Shin Poong Pharm. Co., Ltd.. Kate A Hanneman - Other; Sanofi Genzyme. Jody Shen - Employment; Shin Poong Pharm. Co., Ltd.. A. Claire Claire Watkins - Other; Gore, CryoLife.

IM.CVS.638: Success in Failure: Novel Applications of Imaging in Heart Failure with Preserved EF

DESCRIPTION:

Session on new insights into the physiopathology of HFpEF

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Jae K Oh, Rochester - None.

Otto Smiseth, Oslo - None.

Erwan Donal - Honoraria; Novartis, Bristol Myers Squibb, Other Research Support; General Electric Healthcare.

IM.CVS.658: Acute Chest Pain: Imaging Controversies

DESCRIPTION:

Fast paced session covering controversies related to acute chest pain imaging in the ED.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Dominika Sucha - None.

Maureen Pearl Kohi - None.

Quynh Truong - None.

Phillip M Young - Honoraria; Arterys.

Michael Lanspa - Honoraria; American Thoracic Society, Society of Critical Care Medicine, American Society of Echocardiography.

Akhilesh Sista - Other Research Support; Penumbra, Inc., Research Grant; National Institutes of Health.

Antoinette S Gomes - Stock Shareholder; Pfizer, Abbott Laboratories.

IM.ME.713: Hype or Hope? Artificial Intelligence and Machine Learning in Imaging

DESCRIPTION:

This session will start with an introduction to scientific basis of AI and ML, followed by the use of these techniques to select appropriate imaging, to make diagnoses, and the guide therapies. Finally, there will be a summary of the important aspects of this topic, including implications for medical ethics.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Alex Bratt - None. David Ouyang - None. Marielle Scherrer-Crosbie - None. Tessa Cook - Honoraria; Osler Institute, Visiting scholar at RadPartners AI Summit, Research Grant; RSNA, ACR, SIIM. Geoffrey D. Rubin - Honoraria; Boehringer Ingelheim, Other; General Electric Healthcare, Nanox, Heartflow, Fovia.

David Playford - Honoraria; Alerte Echo IQ.

Damini Dey - Other; Cedars-Sinai Medical Center .

IN.CVS.690: Dilemmas and Controversies in TAVR

DESCRIPTION:

Leaders in cardiology will help clinicians to identify optimal timing of TAVR after an ischemic event and utility in aortic insufficiency.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Mina Madan - None.

Pedro A Villablanca - None.

Suzanne J Baron - Other; Abiomed, Boston Scientific Corporation, Research Grant; Boston Scientific Corporation.

Saif Anwaruddin - Honoraria; V wave, Other; Medtronic, Other Research Support; Boston Scientific , Speaker/Speaker's Bureau; Edwards Lifesciences, Medtronic.

Kendra Janel Grubb - Honoraria; Medtronic, Ancora, Speaker/Speaker's Bureau; Medtronic, Boston Scientific, Edwards Lifesciences.

Binita Shah - Other; Philips Volcano, Radux, Terumo Medical.

Adnan Chhatriwalla - Honoraria; Boston Scientific, Other; Edwards Lifesciences, Medtronic Inc, Research Grant; Boston Scientific, Speaker/Speaker's Bureau; Abbott Vascular, Edwards Lifesciences, Medtronic Inc.

IN.HL.701: The Evolving Field of Percutaneous Ventricular Assist Devices: Who and When

DESCRIPTION:

Session on the patient in cardiac arrest

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:Natalia Pinilla Echeverri- Honoraria; Conavi, Speaker/Speaker's Bureau; Abbott.Giselle Adriana Baquero- Other; Boston Scientific.Ajay Kirtane - Other; Several.- Other; Several.

IN.ME.573: The Changing Landscape in the Management of Stable Ischemic Heart Disease

DESCRIPTION:

This session will begin with a keynote speaker outlining the changing landscape in the management of patients with SIHD, followed by case presentation and viewpoints regarding the management and a panel discussion emphaziing the importance of an individualized approach to care.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.50 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.50 Contact Hours. Universal Program Number: JA0000134-0000-20-131-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Bernard J Gersh	None.
Garima Sharma	None.
Garima Sharma	None.
Garima Sharma	None.

Leslee J Shaw	None.
William E Boden II	Honoraria; Bristol-Myers Squibb, Other; Amarin, Research Grant; Amarin Pharmaceuticals, Abbvie, Speaker/Speaker's Bureau; Amgen, Janssen Pharmaceuticals.
Sripal Bangalore	Honoraria; Biotronik, Pfizer, Amgen, Abbott Vascular, Research Grant; Abbott Vascular.
Pamela S Douglas	Honoraria; Elsevier (spouse), Konica Minolta Inc (spouse), UptoDate/Kluwer, Other; Exploragen (spouse), Fabric genomics (spouse), Research Grant; Abbott (spouse), heartflow, Kowa, Stock Shareholder; Origin commercial advisors (spouse), Peer medical (spouse), Predigen (spouse), MeTree (spouse), Stock Shareholder; Pappas ventures.
Judith S Hochman	Employment; NYUSOM, Other; Amgen, Inc, Abbott Vascular, Medtronic, Inc;, St Jude Medical, Inc, Volcano Corp, Merck Sharp & Dohme Corp, Omron Healthcare, Inc, Other Research Support; AstraZeneca Pharmaceuticals, LP, Arbor Pharmaceuticals, LLC, Research Grant; NIH/NHLBI grant support for ISCHEMIA Trial.
Jacqueline E Tamis- Holland	Other; Merck , Speaker/Speaker's Bureau; Medscape.
Gregg W Stone	Other; Shockwave, Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Speaker/Speaker's Bureau; Cook.

LBS.01: Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients, and More

DESCRIPTION:

Clinical trial data will be presented and challenge our therapeutic approaches to heart failure and atrial fibrillation.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Christine M Albert,

Nancy R Cook, Julie Pester, Manickavasagar Vinayagamoorthy, Claire Ridge, Jacqueline Suk Danik, Baris Gencer, Hasan K Siddiqi, Chee Ng, Heike Gibson, Samia Mora, Julie Elizabeth Buring, JoAnn E Manson C.M. Albert: Research Grant; St. Jude Medical, Abbott, Roche. N.R. Cook: None. J. Pester: None. M. Vinayagamoorthy: None. B. Gencer: None. H.K. Siddiqi: None. C. Ng: None. H. Gibson: None. S. Mora: Speaker/Speaker's Bureau; Quest Diagnostics. J.E. Buring: None. J.E. Manson: None.

Piotr Ponikowski, Stefan

D Anker, Bridget-Anne Kirwan, Dorobantu Maria, Jaroslaw Drozdz, Vincent Fabien, Gerasimos Filippatos, Tim Friede, Udo-Michael Goehring, Andre KEren, Irakli Khintibidze, Hans Kragten, Felipe A Martinez, Theresa McDonagh, Marco Metra, Davor Milicic, Jose C Nicolau, Marcus Ohlsson, Alexander Parhomenko, Domingo Pascual Figal, frank ruschitzka, David Sim, Hadi Skouri, Peter D Van Der Meer, Ewa A Jankowska

P. Ponikowski: Speaker/Speaker's Bureau; Vifor Pharma. Honoraria; Vifor Pharma. Other; Vifor Pharma. S.D. Anker: Research Grant; Abbott Vascular, Vifor. Honoraria; Vifor, Bayer, Boehringer Ingelheim. B. Kirwan: None. D. Maria: None. J. Drozdz: None. V. Fabien: Employment; VIFOR PHARMA - Full-time employee. G. Filippatos: Other; Servier, Bayer, Vifor, Boehringer Ingelheim, Medtronic. T. Friede: Honoraria; AstraZeneca, Janssen, Roche, Boehringer Ingelheim, Daiichi-Sankyo, Galapagos, Penumbra, Vifor, BiosenseWebster, CSL Behring, Fresenius Kabi, Coherex Medical. A. KEren: None. I. Khintibidze: None. H. Kragten: None. F.A. Martinez: Honoraria; Astrazeneca, Boheringer Inghelhein, Novartis. Research Grant; Vifor, BMS. Speaker/Speaker's Bureau; Pfizer. T. McDonagh: Honoraria; Vifor, Astra Zeneca, Corpus. M. Metra: Honoraria; Modest; Amgen, Vifor pharma, WindTree Therapeutics, Astra-Zeneca, Actelion, LivaNova, Abbott Vascular. Speaker/Speaker's Bureau; Abbott Vascular, Edwards therapeutics. J.C. Nicolau: Other; Sanofi. Research Grant; Sanofi, Esperion, Amgen, Bayer, Astrazeneca, Vifor, CSL Behring, Dalcor, Novartis, NovoNordisk. Honoraria; Modest; Servier, Daiichi-Sankyo. M. Ohlsson: None. D. Pascual Figal: Speaker/Speaker's Bureau; Vifor Pharma, Servier, Abbot, Pizer, Novartis. Research Grant; Astra Zeneca, Roche diagnostics. F. ruschitzka: Other; Novartis, Servier, Bayer, Abbott/St. Jude Medical, Astra Zeneca, ESC, A+ Science AB/Astra Zeneca, Amgen, Boehringer Ingelheim, Brigham and Women's Hospital Boston, Fresenius, IMC/Astra Zeneca, Klub Class, Novartis, Novartis, Radcliffe Group, Servier, Stiftung Pfizer Forschungspreis, Swiss National Foundation, WebMD/Medscape. D. Sim: None. H. Skouri: Honoraria; servier. Speaker/Speaker's Bureau; Novartis. Honoraria; Asra Zeneca, Abbott, Medtronic, Boehringer Ingelheim. P.D. Van Der Meer: Research Grant; vifor pharma, Ionis, Astra Zeneca, Pfizer. Speaker/Speaker's Bureau; Modest; vifor pharma, Servier, Novartis. E.A. Jankowska: Speaker/Speaker's Bureau; Vifor Pharma. Honoraria; Vifor Pharma. Other; Vifor Pharma.

John R Teerlink, Rafael Diaz, G. Michael Felker, Marco Metra, John J McMurray, Scott D Solomon, Lucie A Sharpsten, Jason C Legg, Siddique A Abbasi, Fady I Malik, Christopher E Kurtz, GALACTIC-HF Committees, Investigators and Patients

J.R. Teerlink: Research Grant; Abbott, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Cytokinetics, Bayer, Medtronic. Honoraria; AstraZeneca. R. Diaz: Research Grant; DALCOR, MHICC, PHRI, AMGEN, AMARIN. Speaker/Speaker's Bureau; SANOFI. G. Felker: Research Grant; Roche Diagnostics, Amgen, Bayer, Merck. Honoraria; Amgen, BMS, Medtronic, Cytokinetics, Roche Diagnostics, Novartis. M. Metra: Honoraria; Amgen, Abbott Vascular, Vifor pharma, WindTree Therapeutics, Astra-Zeneca, Actelion, LivaNova. Speaker/Speaker's Bureau; Abbott Vascular, Edwards therapeutics. J.J. McMurray: Other; Bayer, Cardiorentis, Amgen, Oxford University/Bayer, Theracos, Abbvie, Dalcor, Pfizer, Merck, Novartis, Glaxo Smith Kline (GSK), Bristol Myers Squibb (BMS), Vifor-Fresenius, Kidney Research UK (KRUK), Novartis, AstraZeneca. S.D. Solomon: Research Grant; Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, Neurotronik, NIH/NHLBI, Novartis, Respicardia, Sanofi Pa. Other; Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GSK, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, C. L.A. Sharpsten: Employment; Amgen. Stock Shareholder; Amgen. J.C. Legg: Employment; Amgen. Stock Shareholder; Amgen. S.A. Abbasi: Employment; Amgen. F.I. Malik: Employment; Cytokinetics, Inc. Stock Shareholder; Cytokinetics, Inc. C.E. Kurtz: Employment; Amgen, Inc. Stock Shareholder; Amgen, Inc.

Paul A Heidenreich Renate B Schnabel Nasrien E Ibrahim Marc A Pfeffer	None. Honoraria; BMS/Pfizer. Honoraria; Novartis, Roche. Honoraria; AstraZeneca, Corvidia, GlaxoSmithKline, Jazz, MyoKardia, Novartis, Roche, Sanofi and Servier, Other; DalCor, Novo Nordisk, Ownership Interest; DalCor, Research Grant; Novartis.
John J McMurray	Other; Bayer, Cardiorentis, Amgen, Oxford University/Bayer, Theracos, Abbvie, Dalcor, Pfizer, Merck, Bristol Myers Squibb (BMS), Vifor-Fresenius, Kidney Research UK (KRUK), Novartis, Glaxo Smith Kline (GSK), AstraZeneca.
Eldrin F Lewis	Other; Merck, Novartis, Dal-Cor, Research Grant; NHLBI, Sanofi, Novartis, Merck.
Biykem Bozkurt	Honoraria; Bristol Myers Squibb, scPharmaceuticals, Inc , Baxter Health Care Corporation, Sanofi Aventis Pharmaceuticals , Relypsa, Other; Respicardia Registry, ABBOTT VASCULAR, Liva Nova .
LBS.04: Fish Oil, Fancy Drugs, and Frustrations in Lipid Management

DESCRIPTION:

Compelling clinical science which may help us better understand the story of lipid therapy.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

A Lincoff, Stephen J Nicholls, Michelle Garcia, Dianna Bash, Christie M Ballantyne, Philip Barter, Michael H DAVIDSON, John Jp Kastelein Jr., Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian, Terje Rolf Pedersen, Paul M Ridker, Kausik Ray, Brian Katona, Anders Himmelmann, Larrye Ellis Loss, Martin Rensfeldt, Torbjorn Lundstrom, Rahul Agrawal, Kathy Elizabeth Wolski, Steven E Nissen, for the STRENGTH Trial Investigators

A. Lincoff: Research Grant; Astra Zeneca, AbbVie, CSL, Novartis, Esperion. Honoraria; Eli Lilly, Novo Nordisk. S.J. Nicholls: Research Grant; AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience. Honoraria; AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. M. Garcia: None. C.M. Ballantyne: Research Grant; Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic. Other; Abbott Diagnostics, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Novartis, Novo Nordisk, Regeneron, Sanofi-Synthelabo, Corvidia, Pfizer. M.H. Davidson: Speaker/Speaker's Bureau; Amgen, Regeneron, Sanofi. Employment; Corvidia Therapeutics. J.J. Kastelein: Other; Astra Zeneca, Novartis, Novo Nordisk, Pfizer, Regeneron. W. Koenig: Other; AstraZeneca, Pfizer, The Medicines Company, Corvidia, Daiichi-Sankyo, Genentech, Novartis, DalCor, Kowa, Amgen. Honoraria; AstraZeneca, Sanofi. Research Grant; Roche Diagnostics, Beckmann, Singulex, Abbott, Berlin-Chemie, Bristol-Myers Squibb, Novartis, Amgen. D.K. McGuire: Other Research Support; AstraZeneca, Sanofi, Boehringer Ingelheim. Merck & Company, Pfizer, Novo Nordisk, Eisai Inc, Esperion, Lilly USA, GlaxoSmith Kline, Janssen, Lexicon. Akebia, AbbVie, Eidos, Arena, Dynavax, Otsuka, CSL Behring. Honoraria; Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Metavant, Applied Therapeutics, Sanofi, AstraZeneca, GlaxoSmithKline, Afimmune. D. Mozaffarian: Research Grant; National Institutes of Health, Gates Foundation. Other; GOED, Nutrition Impact, Pollock Communications, Bunge, Indigo Agriculture, Amarin, Acasti Pharma, Cleveland Clinic Foundation, America's Test Kitchen, Danone, Elysium Health, Filcitrine, Omada Health, DayTwo, UpToDate. T.R. Pedersen: Speaker/Speaker's Bureau; Amgen, Sanofi. P.M. Ridker: Research Grant; Kowa, Novartis, NHLBI, Amarin, Honoraria; Novartis, J&J, Merck, Sanofi, Amarin, Peter Munk Toronto, Pfizer, Baim Institute, Cleveland Clinic, Civi Biopharm, Iqvia, Corvidia. K. Ray: Research Grant; Amgen, Sanofi, Daiichi Sankyo, Regeneron, MSD, Pfizer. Honoraria; Amgen, Sanofi, Regeneron, Esperion, Medicines Company, Boehringer Ingelheim, Novo Nordisk, Kowa, Resverlogix, Dr Reddys, Cipla, Algorithm, Zuelling Pharma, Silence Therapeutics, Cerenis, Lilly, Astra Zeneca, Bayer, Akcea, MSD, Novartis, Daiichi Sankyo. B. Katona: Employment; AstraZeneca. Stock Shareholder; AstraZeneca. A. Himmelmann: Employment; AstraZeneca. L.E. Loss: Employment; AstraZeneca. M. Rensfeldt: Employment; AstraZeneca. K.E. Wolski: None. S.E. Nissen: Research Grant; Astra Zeneca, Amgen, Pfizer, Novartis, Esperion, Eli Lilly, AbbVie, MyoKardia, Silence Therapeutics, Medtronic.

Robert S Rosenson,

Lesley J Burgess, Christoph F Ebenbichler, Shazia Ali, Robert Hamlin, Robert Pordy, Yuping Dong, Vladimir Son, Daniel Gaudet **R.S. Rosenson**: Honoraria; 89Bio, Amgen, Corvidia, CVS Caremark, Kowa, Medicines Company, Regeneron. Other; UpToDate, Inc. Stock Shareholder; MediMergent, LLC. Research Grant; Amgen, Medicines Company, Regeneron, Novartis (all paid to institution). L.J. Burgess: None. C.F. Ebenbichler: None. S. ali: Employment; Regeneron. R. pordy: Employment; Regeneron Pharmaceuticals. V. Son: Employment; Regeneron Pharmaceuticals, Inc. D. Gaudet: Research Grant; Regeneron, Acasti, Akcea, Applied Therapeutics, Arrowhead, Esperion, Gemphire, HDL Therapeutics, Institut de cardiologie de Montréal, Kowa, Novartis, Prizer, Sanofi, The Medicine Company, UniQure, AstraZeneca, Canadian Cardiovascular Research Network, Cerenis, Dalcor Pharma. Honoraria; Regeneron, Akcea, Allergan, Amryt pharma, Arrowhead, HDL Therapeutics, Novartis, Sanofi.

Are Annesoenn A

Kalstad, Peder L Myhre, Sjur Hansen Tveit, Laake Kristian, Svein Solheim, Arnljot Tveit, Erik B Schmidt, Pal Johan Smith, Morten Fagerland, Dennis W Nilsen Sr., Ingebjorg Seljeflot, Harald Arnesen **A.A. Kalstad**: None. P.L. Myhre: Speaker/Speaker's Bureau; Novartis. S. Tveit: None. S. Solheim: None. A. Tveit: None. M. Fagerland: None. D.W. Nilsen: None. I. Seljeflot: None. H. Arnesen: None.

James Philip Howard,

Frances Wood, Judith Finegold, Alexandra Nowbar, David Thompson, Ahran D Arnold, Christopher Rajkumar, Stride B Christopher, susan connolly, Jaimini Cegla, Peter Sedgwick Sever, Christine Norton, Simon Thom, Matthew Shun-Shin, Darrel Francis J.P. Howard: None. A. Nowbar: None. D. Thompson: None. A.D. Arnold: Honoraria; Medtronic. Other; Bayer. C. Rajkumar: None. S. connolly: Honoraria; Astra Zeneca. P.S. Sever: Research Grant; Pfizer, Amgen. Speaker/Speaker's Bureau; Amgen. C. Norton: None. S. Thom: None. M. Shun-Shin: None. D. Francis: None.

Chiadi E Ndumele None.

Tracy Y Wang	Research Grant; Abbott, BMS, Boston Scientific, Merck, Portola,
	Chiesi, AstraZeneca, Cryolife, Regeneron.

Karol E Watson	Honoraria; Amgen, Amarin, Esperion, Boehringer Ingelheim.
George Thanassoulis	Other; Amgen, Sanofi/Regeneron, Research Grant; Ionis, Servier, Speaker/Speaker's Bureau; Amgen, Sanofi/Regeneron.
Francine K Welty	Other; Boehringer Ingelheim.

Alberico L Catapano Honoraria; Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Ionis Pharmaceuticals, Mylan, Menarini, Merck, Recordati, Regeneron Daiichi Sankyo, Astrazeneca, Aegerion, Amryt, Sandoz, Other; Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Ionis Pharmaceuticals, Mylan, Menarini, Merck, Recordati, Regeneron Daiichi Sankyo, Genzyme, Aegerion, Sandoz, Other Research Support; SigmaTau, Menarini, kowa, Recordati, Eli Lilly, Research Grant; Pfizer, Merck, Sanofi, Regeneron, Mediolanum, Amgen, Speaker/Speaker's Bureau; Merck, Sanofi, Regeneron, Pfizer, AstraZeneca, Amgen, Sigma Tau, Recordati, Aegerion, Kowa, Menarini, Eli Lilly, Amryt, Sandoz, Amarin.

LBS.07: Randomized Trials – Brain, Kidney, and Heart

DESCRIPTION:

Promising medications from clinical trial results in diabetes, heart failure, and stroke.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.50 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Allan Klein, Paul C Cremer, Antonio Brucato, Antonio Abbate, Fang Fang, Antonella Insalaco, Martin M Lewinter, Basil S Lewis, David Lin, Sushil Allen Luis, Stephen Nicholls, Arian Pano, Alistair Wheeler, Liangxing Zou, John F Paolini

A. Klein: Research Grant; Kiniksa. Honoraria; Sobi, Wolters Kluwer, Elsevier, Pfizer. M. Imazio: Other; KINIKSA, SOBI. P.C. Cremer: None. A. brucato: Research Grant; ACARPIA, SOBI. Other; SOBI, KINIKSA. A. Abbate: Honoraria; Merck, Serpin Pharma, GSK, Novo Nordisk, Cromos Pharma. Research Grant; Swedish Orphan Biovitrum, Olatec, Novartis. F. Fang: None. M.M. Lewinter: None. B.S. Lewis: Honoraria; MSD, Kiniksa. Research Grant; KOWA. D. Lin: None. S.A. Luis: Other; Kiniksa Pharmaceuticals, SOBI Pharmaceuticals. S. Nicholls: Research Grant; AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience. Honoraria; AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. A. pano: None. L. Zou: None. J.F. Paolini: Employment; Kiniksa Pharmaceuticals Corp. Stock Shareholder; Kiniksa Pharmaceuticals Corp.

Pierre Amarenco, Hans Denison, Scott R Evans, Anders Himmelmann, Stefan James, Mikael Knutsson, Per Ladenvall, Carlos Molina, Yongjun Wang, Claiborne Johnston **P. Amarenco**: Research Grant; Pfizer, AstraZeneca, Sanofi, BMS, Merck, Boston Scientific. Honoraria; Bayer, Amgen, Kowa, GSK, Fibrogen, Shing Poon. H. Denison: Employment; AstraZeneca. S.R. Evans: Other; Astrazenica. A. Himmelmann: Employment; AstraZeneca. S. James: Research Grant; Astra Zeneca, The Medicines Company, Medtronic. M. Knutsson: Employment; AstraZeneca. P. Ladenvall: Employment; AstraZeneca R&D. C. Molina: None.

Alasdair J Gray, Carl

Roobottom, Jason E Smith, Steve Goodacre, Katherine Oatey, O'Brien Rachel, Robert F Storey, Lee J Robert, Steff E Lewis, Praveen Thokala, Newby E David **A.J. Gray**: None. J.E. Smith: None. R.F. Storey: Other; AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer alliance. Other; Modest; Amgen, Thromboserin, Haemonetics, GlyCardial Diagnostics, Portola.

Deepak Bhatt, Michael Szarek, Philippe Steg, Christopher Cannon, Lawrence Leiter, Darren McGuire, Julia Lewis, Matthew Riddle, Adriaan Voors, Marco Metra, Lars Lund, Michel Komajda, Jeffrey Testani, Christopher Wilcox, Piotr Ponikowski, Renato Lopes, Subodh Verma, Pablo Lapuerta, Bertram Pitt, on Behalf of the SOLOIST-WHF Investigators

D.Bhatt: Research Grant; Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laborato. M.Metra: Honoraria; Amgen, Abbott Vascular, Vifor pharma, WindTree Therapeutics, Astra-Zeneca, Actelion, LivaNova, Speaker/Speaker's Bureau; Abbott Vascular, Edwards therapeutics. L.Lund: Honoraria; Novartis, Merck, Sanofi, AstraZeneca, ViforPharma, Bayer, Pharmocosmos, Research Grant; Novartis, Boehringer Ingelheim, Boston Scientific, Speaker/Speaker's Bureau; Abbott, Medscape. M.Komajda: n/a. J.Testani: Honoraria; bayer, BMS, Boehiringer, Megentamed, Novartis, Windtree therapeutics, Cardionomic, Seguana, Reprieve medical, FIRE1, Gore, AZ, Research Grant; 3ivelabs, BMS, Boehiringer, Otsuka, Sequana, Sanofi, Sanofi, Abbott. C.Wilcox: None. P.Ponikowski: Honoraria; Vifor Pharma, Other; Vifor Pharma, Speaker/Speaker's Bureau; Vifor Pharma. R.Lopes: Other; Bayer, Boehringer Ingleheim, Daiichi Sankyo, Glaxo Smith Kline, Medtronic, Merck, Portola, Sanofi, Bristol-Myers Squibb, Pfizer Other Research Support; Bristol-Myers Squibb, Glaxo Smith Kline, Medtronic, Pfizer, Sanofi. S.Verma: Honoraria; Amgen, Janssen, Boehringer-Ingelheim/Lilly, Merck, Bayer, Novonordisk, EOCI, HLS Therapeutics, Novartis, Sanofi, Sun Pharma, Toronto Knowledge Translation Working Group, AstraZeneca, Research Grant; Amgen, Boehringer-Ingelheim/Lilly, Bristol-Myers Squibb, HLS Therapeutics. P.Lapuerta: n/a. B.Pitt: Honoraria; Astra Zeneca, Honoraria; Sanofi, Bayer, vifor Stock Shareholder; KBP pharmaceuticals, scpharmaceuticals, sarfez, SQinovations, G3 pharmaceuticals, Cereno scienmtific. M.Szarek: Other Research Support; CiVi, Esperion, Regeneron Pharmaceuticals, Sanofi. P.Steg: Honoraria; Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Idorsia, Lilly, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi, Servier. Research Grant; Bayer, Merck, Sanofi, Amarin, Servier. C.Cannon: Honoraria; Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer Rhoshan, Sanofi. Research Grant; Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Pfizer. L.Leiter: Other; Astra Zeneca, Amgen, Kowa, Merck, The Medicines Company, Sanofi/Regeneron, Boehringer Ingelheim, Eli Lilly, Janssen, HLS, Bayer, Novartis, Other Research Support; Sanofi/Regeneron, Esperion, Eli Lilly, GSK. On behalf of the soloistwhf investigators: n/a.

Gerasimos Filippatos,

Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Peter Rossing, Luis M Ruilope, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph, George L Bakris

G. Filippatos: Research Grant; Bayer, Vifor, Medtronic, Boehringer Ingelheim, Novartis, Sanofi. S.D. Anker: Research Grant; Abbott Vascular, Vifor. Honoraria; Vifor. Honoraria; Modest; Bayer, Boehringer Ingelheim. R. Agarwal: Research Grant; GlaxoSmithKline. Other; Akebia, Bayer, Johnson & Johnson, Boehringer Ingelheim, Takeda, Daiichi Sankyo, Amgen, AstraZeneca, Sanofi, Celgene, Reata, Relypsa, GlaxoSmithKline, Gilead, ER Squibb and Sons, Fresenius, Ironwood Ph., American Journal of Nephrology, Nephrology Dialysis and Transplantation, UpToDate. B. Pitt: Other; Bayer, Astra Zeneca, Sanofi/Lexicon, KBP Pharmaceuticals, Relypsa/Vifor. P. Rossing: Other; Bayer, Astellas, Astra Zeneca, Boehringer ingelheim, Novo Nordisk, Gilead, Mundipharma, Merck, Vifor, Sanofi. L.M. Ruilope: Speaker/Speaker's Bureau; Medtronic, Bayer. Honoraria; Daiichi-Sankyo, Novartis, Sanofi. Research Grant; Astra Zeneca. P. Kolkhof: Employment; BAYER AG. P. Schloemer: Employment; Bayer AG. I. Tornus: Employment; Bayer AG. Stock Shareholder; Bayer AG. A. Joseph: Employment; Bayer AG. G.L. Bakris: Honoraria; Merck, Novo Nordisk, Relypsa, Astra-Zeneca.

Deepak Bhatt, Michael Szarek, Bertram Pitt, Christopher Cannon, Lawrence Leiter, Darren McGuire, julia B lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod, David Cherney, Jamie P Dwyer, Benjamin M Scirica, Clifford J Bailey, Rafael Díaz, Kausik K Rav, Jacob A Udell, Renato D Lopes, Pablo Lapuerta, Philippe Gabriel Steg, on Behalf of the SCORED Investigators

D. Bhatt: Research Grant; Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laborato. M. Szarek: Other Research Support; Regeneron Pharmaceuticals, Sanofi, CiVi, Esperion. B. Pitt: Honoraria; Sanofi. Honoraria; Astra Zeneca, Bayer, vifor. Stock Shareholder; KBP pharmaceuticals, scpharmaceuticals, sarfez, SQinovations, G3 pharmaceuticals, Cereno scienmtific. L. Leiter: Research Grant; Astra Zeneca, Amgen, Kowa, The Medicines Company, Boehringer Ingelheim, Janssen, Bayer, Novartis. Other Research Support; Sanofi/Regeneron, GSK, Esperion, Eli Lilly Other; Astra Zeneca, Amgen, Kowa, Merck, The Medicines Company, Sanofi/Regeneron, Boehringer Ingelheim, Eli Lilly, Bayer, Novartis. Other; Modest; Janssen, HLS. Speaker/Speaker's Bureau; AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Sanofi, Amgen, Servier. D. McGuire: Other Research Support; AstraZeneca, Sanofi, Boehringer Ingelheim, Merck & Company, Pfizer, Novo Nordisk, Eisai Inc, Esperion, Lilly USA, GlaxoSmith Kline, Janssen, Lexicon, Akebia, AbbVie, Eidos, Arena, Dynavax, Otsuka, CSL Behring. Honoraria; Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Metavant, Applied Therapeutics, Sanofi. Honoraria; Modest; AstraZeneca, GlaxoSmithKline, Afimmune. J.B. lewis: Other; sanofi, CSL. Other; chair cardiorenal advisory committee FDA. M.N. Kosiborod: Research Grant; AstraZeneca, Boehringer Ingelheim. Honoraria; Amarin, Applied Therapeutics, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Eisai, Glytec, GSK, Intarcia, Janssen, Eli Lilly, Merck (Diabetes), Novartis, Novo Nordisk, Sanofi. D. Cherney: Other; Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, AstraZeneca, Merck & Co Inc., Novo Nordisk, Prometic, Sanofi, Bristol-Myers Squibb, Mitsubishi-Tanabe, MAZE, Bayer. B.M. Scirica: Honoraria; AstraZeneca, Eisai. Research Grant; Eisai, Novartis, Merck. Honoraria; NovoNordick, Boerhinger Ingelheim. Expert Witness; AbbVie. Other; Allergan. C.J. Bailey: Other; Modest; Abbott, Lexicon, Sanofi. Honoraria; Astra Zeneca, Boehringer Ingelheim, Merck, Napp, Novo. K.K. Ray: Research Grant; Significant; Amgen, Sanofi, Regeneron, MSD, Pfizer, Daiichi Sankyo. Honoraria; Amgen, Sanofi, Regeneron, Esperion, Medicines Company, Boehringer Ingelheim, Novo Nordisk, Kowa, Resverlogix, Dr Reddys, Cipla, Algorithm, Zuelling Pharma, Silence Therapeutics, Cerenis, Lilly, Astra Zeneca, Bayer, Akcea, MSD, Novartis, Daiichi Sankyo. J.A. Udell: Research Grant; Boehringer-Ingelheim, Sanofi. Honoraria; Boehringer-Ingelheim, Novartis, Sanofi. R.D. Lopes: Other Research Support; Bristol-Myers Squibb, Pfizer, Glaxo Smith Kline, Medtronic, Sanofi. Other; Bayer, Boehringer Ingleheim, Bristol-Myers Squibb, Daiichi Sankyo, Glaxo Smith Kline, Medtronic, Merck, Pfizer, Portola, Sanofi. P.G. Steg: Research Grant; Bayer, Merck, Sanofi, Amarin, Servier. Honoraria; Amarin, Amgen, AstraZeneca, Bayer/Janssen, BoehringerIngelheim, Bristol-Myers-Squibb, Idorsia, Lilly, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi, Servier.

Louise D McCullough	None.
M Chadi M Alraies	None.
Mitchell S Elkind	Other; UpToDate, Other Research Support; BMS-Pfizer Alliance for Eliquis, Research Grant; Roche.
Maria Bahit	Other; VIFOR, Pfizer, CSL Behring.
Judith S Hochman	Employment; NYUSOM, Other; Amgen, Inc, Abbott Vascular, Medtronic, Inc;, St Jude Medical, Inc, Volcano Corp, Merck Sharp & Dohme Corp, Omron Healthcare, Inc, Other Research Support; AstraZeneca Pharmaceuticals, LP, Arbor Pharmaceuticals, LLC, Research Grant; NIH/NHLBI grant support for ISCHEMIA Trial.
Jane E Wilcox	Other; Cytokinetics, Speaker/Speaker's Bureau; Medtronic, Boehringer Ingelheim.
Christoph Wanner	Honoraria; Lilly, AstraZeneca, MSD, Sanofi, Mundipharma, Boehringer Ingelheim.

Brendan M Everett

Other; Roche Diagnostics, NIDDK, US FDA, Circulation, UpToDate, Merck, Gilead, Amgen, Research Grant; Novartis, NHLBI.

LBS.09: High Tech or High Touch: Creative Strategies to Optimize Patient Care

DESCRIPTION:

Clinical trials that are making strides in a digital interventions to improve cardiovascular patient care.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Benjamin M Scirica,

Christopher P Cannon, Naomi D Fisher, Thomas A Gaziano, David Zelle, Kira Chaney, Angela M Miller, Hunter Nichols, Lina Matta, William J Gordon, Sean N Murphy, Kavishwar Wagholikar, Jorge Plutzky, Calum Macrae, on behalf of the DCT Team **B.M. Scirica:** Honoraria; AstraZeneca, Eisai, NovoNordick, Boerhinger Ingelheim. Research Grant; Eisai, Novartis, Merck. Expert Witness; AbbVie. Other; Allergan. C.P. Cannon: Research Grant; Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Pfizer. Honoraria; Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer Rhoshan, Sanofi. T.A. Gaziano: Research Grant; NIH, Novartis. Other; Amgen. D. Zelle: None. K. Chaney: None. H. nichols: None. L. Matta: None. W.J. Gordon: Honoraria; Office of the National Coordinator for Health IT. Research Grant; IBM Watson. K. Wagholikar: None. J. Plutzky: Other; Amgen, Novartis, Novo Nordisk, sanofi, Vivus. Research Grant; Boehringer Ingelheim. C. Macrae: Research Grant; Verily Life Sciences, Astra Zeneca, NIH, Quest Diagnostics.

Larry A Allen, Grace

Venechuk, Colleen K McIlvennan, Robert Lee Page II, Christopher Knoepke, Laura J Helmkamp, Prateeti Khazanie, Pamela Peterson, Kenneth Pierce, Jocelyn S Thompson, Tristan Dow, Lance C Richards, Janice V Huang, James R. Strader, Katy E Trinkley, David P Kao, David J Magid, Peter M Buttrick, Daniel D Matlock L.A. Allen: Research Grant; American Heart Association, PCORI, NIH. Other; Janssen, Boston Scientific, ACI Clinical, Duke Clinical Research Institute, Amgen, Cytokinetics, Abbott. G. Venechuk: None. C.K. McIlvennan: None. R.L. Page: None. C. Knoepke: Research Grant; American Heart Association (Career Development Award). L.J. Helmkamp: None. P. Khazanie: None. P. Peterson: Other; American Heart Association. Research Grant; NHLBI. K. Pierce: None. J.S. Thompson: None. T. Dow: None. L.C. Richards: Stock Shareholder; Phizer, Moderna, Gilead. J.V. Huang: None. K.E. Trinkley: None. D.P. Kao: Research Grant; National Heart, Lung, Blood Institute, American Heart Association. Other; Medtronic. Ownership Interest; Codex, Inc.. Honoraria; Inova Heart Failure Collaboratory. D.J. Magid: None. P.M. Buttrick: None.

Nancy M Albert, Kathy

Ray, James F. Bena, Shannon L. Morrison, Mary Marino, Celia Painter **N.M. Albert**: Other Research Support; Novartis Pharmaceutical Corp. Honoraria; Amgen, AstraZeneca. K. Ray: None. J.F. Bena: None. S.L. Morrison: None. C. Painter: None.

Rajesh Vedanthan, Jemima Kamano, Stavroula Chrysanthopoulou, B Richard Mugo, Benjamin Andama, Gerald S Bloomfield, Cleophas Chesoli, Allison DeLong, David Edelman, Eric Finkelstein, Carol Rose Horowitz, Simon Manyara, Diana Menya, Violet Naanyu, Vitalis Orango, Sonak Pastakia, Thomas Valente, Joseph Hogan, Valentin Fuster	R. Vedanthan : None. J. Kamano: None. S. Chrysanthopoulou: None. R. Mugo: None. B. Andama: None. G.S. Bloomfield: None. C. Chesoli: None. A. DeLong: None. D. Edelman: None. E. Finkelstein: None. C.R. Horowitz: None. S. Manyara: None. D. Menya: None. V. Naanyu: None. V. Orango: None. S. Pastakia: Other; Abbott, BD. T. Valente: None. J. Hogan: None. V. Fuster: None.
lleana L Pina	None.
Seth S Martin	Honoraria; Amgen, Sanofi, Regeneron, Akcea, Esperion, Astra Zeneca, Novo Nordisk, Other Research Support; Apple, Google, Nokia/Withings, iHealth, Research Grant; Aetna Foundation, American Heart Association, Maryland Innovation Initiative.
Stephen J Greene	Other; Amgen, Cytokinetics, Merck, Other Research Support; AztraZeneca, Amgen, Bristol-Myers Squibb, Novartis, Research Grant; Novartis.
Mark D Huffman	Employment; American Medical Association, Other; American Heart Association, World Heart Federation, Other Research Support; World Heart Federation via unrestricted educational grants from Boehringer Ingelheim, Novartis, and Bupa, Research Grant; American Heart Association, Verily, and AstraZeneca.
Karen E Joynt Maddox	Other; United States Department of Health and Human Services, Research Grant; Commonwealth Fund, NIA, NHLBI.
Freek W Verheugt	Honoraria; Bayer Healthcare, Daiichi-Sankyo, Boehringer-Ingelheim, BMS/Pfizer, AstraZeneca.
Erica S Spatz	Other; Centers for Medicare and Medicaid Services.

LF.CVS.319: Optimal Approaches to a Healthy Lifestyle.

DESCRIPTION:

Active health..." focuses on physical activity". A systems approach to prescribing..." focuses on integration of lifestyle change into practice and health care systems.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of .50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.50 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.50 Contact Hours. Universal Program Number: JA0000134-0000-20-153-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Chiadi Ericson Ndumele - None. Deborah R Young - None. William E Kraus - None. LF.CVS.558: Separating Dietary Facts from Fads: Intermittent Fasting, Paleo, and other Fad Diets -How to have Evidence-Based Conversations about Diet with your Patients

DESCRIPTION:

Separating Dietary Facts from Fads.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-132-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Andrew O Odegaard - None. Karen E Aspry - None. Michael J Wilkinson -None. Paolo Raggi - Other; SANIFIT. Anne N Thorndike - Research Grant; National Institutes of Health (NHLBI and NIDDK).

LF.CVS.561: Cardiovascular Consequences of Vaping and E-Cigs

DESCRIPTION:

A presentation of the cardiovascular consequences of vaping and e-cigs from a multidisciplinary perspective.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-133-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Aruni Bhatnagar - None.

Daniel J Conklin - None.

Mary Rezk-Hanna - None.

Michael J Blaha Honoraria; Amgen Foundation, Sanofi, Bayer, Medicure, Novartis, Novo Nordisk, Zogenix, Tricida, Gilead, Research Grant; NIH, FDA, AHA, Aetna Foundation, Amgen Foundation. Jessica Barrington-Trimis - Employment; Shin Poong Pharm. Co., Ltd.. Emelia J Benjamin - Other; Starting 2020, uncompensated member for MyHeartLab Steering Committee, a PI-initiated study from Samsung to UCSF. PI, Jeffrey Olgin, MD., Research Grant; American Heart Association, 18SFRN34110082, NIH, NHLBI: R01HL128914; 2R01 HL092577; 2U54HL120163; 1R01 HL141434 01A1 NIH, NIA: 1R01AG066010, Robert Wood Johnson, Grant 74624.

LF.CVS.572: State of the Art Lifestyle, Pharmacologic, and Surgical Approaches to Weight Management: What a Cardiologist Needs to Know

DESCRIPTION:

Comprehensive approach to weight management for the practicing clinician. Starts with case presentation and moves on to lifestyle, pharmacologic, and surgical approaches, with final discussion of how to support patients in navigating medical versus surgical options to facilitating weight loss.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-134-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Dimitri Pournaras - None. Kershaw Patel - None. Penny Gordon-larsen - None. Nina Crowley - Employment; Shin Poong Pharm. Co., Ltd.. Jamy Ard - Honoraria; Boehringer Ingelheim, Novo Nordisk, Other Research Support; Boehringer Ingelheim.

Gitanjali Srivastava - Other; Novo Nordisk, Rhythm Pharmaceuticals.

NR.CVS.257: Symptom Science: Promoting Personalized Symptom Management in CVD

DESCRIPTION:

A Didactic lecture-style focusing on the state-of-the-art of Symptom Science and its main components: from identifying biomarkers and measuring their impact on patient-reported outcomes to pointing models to help to understand a phenomenon and develop interventions to act on those. It will be exemplified how a range of symptoms can affect patients in addition to understand the mechanism related to a disease and how patients may respond to interventions.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Dimitri Pournaras - None.

Kershaw Patel - None.

Penny Gordon-larsen - None.

Nina Crowley - Employment; Shin Poong Pharm. Co., Ltd..

Jamy Ard - Honoraria; Boehringer Ingelheim, Novo Nordisk, Other Research Support; Boehringer Ingelheim.

Gitanjali Srivastava - Other; Novo Nordisk, Rhythm Pharmaceuticals.

NR.CVS.291: Ball of Confusion: Interventions to Prevent and Mitigate Cognitive Impairment in CVD

DESCRIPTION:

A Didactic lecture-style focusing on the state-of-the-art of Symptom Science and its main components: from identifying biomarkers and measuring their impact on patient-reported outcomes to pointing models to help to understand a phenomenon and develop interventions to act on those. It will be exemplified how a range of symptoms can affect patients in addition to understand the mechanism related to a disease and how patients may respond to interventions.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-135-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Kenneth M Faulkner - None. Lisa C Bratzke - None. Susan J Pressler - Research Grant; American Heart Association, Research Grant; National Institute of Nursing Research, Agency for Healthcare Research and Quality. Shannon Halloway - Research Grant; Rush University Cohn Scholarship, NIH/NINR R01NR018443. Miyeon Jung - Research Grant; American Heart Association Career Development Award (19CDA34520006), NIH/NINR R01 (R01NR016116).

NR.CVS.401: Who's on First? Teamwork Challenges and Opportunities Across the Continuum

DESCRIPTION:

This session will explore the realities and complexities of teamwork across cardiovascular care settings.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-136-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Deborah L Crabbe - None. Kim S Newlin - Speaker/Speaker's Bureau; Boehringer Ingelheim. Corrine Y Jurgens - Employment; Boston College - Associate Professor. Bruce Warden - Other; Akcea.

NR.CVS.432: Life is Messy: Complex Cardiovascular Comorbidities Across the Lifespan

DESCRIPTION:

This session will examine complex comorbidites in elderly persons with cardiovascular disease, focusing on factors that affect quality of life and outcomes.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Carolyn M Reilly - None. Harleah G Buck - None. Kathryn A Wood - None. Philip Moons - None.
NR.CVS.641: Nursing Science in Review

DESCRIPTION:

This session addresses state of the science and funded researchers present their work.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

<u>The following authors/faculty have declared financial interest(s) and/or affiliations:</u> Barbara Riegel - None. Eunjoo An - None. Foster Osei Baah - None. Jacquelyn Taylor - None. Susan L Dunn - None.

NR.CVS.NS.1479: Cardiovascular Nursing Clinical Symposium Part 2

DESCRIPTION:

Cardiovascular Nursing Clinical Symposium

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Angela L Fink - None.

Juliana Liu - None.

Lucinda J Graven - None.

Kristin E Sandau - Honoraria; Japanese Association of Cardiovascular Nursing, Patient Safety Authority.gov, Other; American Heart Association, Research Grant; Abbott-Northwestern Hospital Foundation (study completed in 2018) (Grant paid to institution).

Daniel J Cantillon - Honoraria; Abbott, Boston Scientific, Stryker Sustainability, Other; Cerner, AirStrip.

PH.CVS.661: Environmental Risk Factors for Pulmonary Hypertension

DESCRIPTION:

This session focuses on environmental risk factors for the development of pulmonary hypertension, especially those that disproportionately affect women in the developing world.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Anubha Agarwal - None.

Ana Mocumbi - None.

Vinicio A De Jesus Perez - None.

Marion Delcroix - Other; Actelion, Bayer/MSD, Acceleron, Research Grant; Actelion, Speaker/Speaker's Bureau; Actelion, Bayer/MSD.

David Montani - Speaker/Speaker's Bureau; Actelion, Bayer, MSD, GSK, Acceleron.

PH.CVS.679: Controversies in the Management of Group 3 Pulmonary Hypertension

DESCRIPTION:

This session will focus on current controversies in the management of pulmonary hypertension associated with lung disease. It will review the epidemiology of the disease and the potential risks and benefits of its treatment.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-137-H04-P P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Thenappan Thenappan - Honoraria; Gilead, Actelion.

Steven Nathan - Honoraria; United Therapeutics, Bellerophon, Speaker/Speaker's Bureau; Boerhinger-Ingelheim, Roche-Genentech.

Corey E Ventetuolo - Honoraria; Acceleron Pharma , Other; CVS Health , Research Grant; United Therapeutics.

PH.CVS.702: Controversies in the Management of Group 2 Pulmonary Hypertension

DESCRIPTION:

The session includes a discussion of PH in Group 2 patients.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-138-H04-PP

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Katharine Clapham - None.

Raymond Benza - Other; Complexa, Gossemer, United Therapeutics.

Mardi Gomberg-Maitland - Other; Acceleron, Actelion, Gossamer Bio, Reata, Neuroderm, United therapeutic, Complexa.

Bradley A Maron - Honoraria; Actelion.

PR.CVS.396: Update in Clinical Lipidology: Emerging and Experimental Lipid Lowering Therapies-Looking Towards the Future of Prevention

DESCRIPTION:

Annual Update in Clinical Lipidology from ATVB/Lifestyle

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Zahid Ahmad - Honoraria; Esperion, Other Research Support; Regeneron, Research Grant; AHA. Sotirios Tsimikas - Employment; Ionis Pharma, Ownership Interest; Kleanthi Diagnostics, Oxitope, Inc.

Rosanne M Crooke - Employment; Ionis Pharmaceuticals.

P Duell Other; Regeneron, Esperion, Retrophin, Regenxbio, Akcea, Research Grant; Retrophin, Regenxbio, Research Grant; Regeneron.

Francine K Welty - Other; Boehringer Ingelheim.

Borge G Nordestgaard - Honoraria; Astra Zeneca, Kowa, Amarin, Regeneron, Akcea, Novo Nordisk, Amgen, Silence Therapeutics.

Anne C Goldberg - Honoraria; Esperion, Other; Merck, National Lipid Association, Research Grant; Amarin, Amgen, Pfizer, Novartis, Regeneron, Sanofi, Ionis/Akcea.

Karol E Watson - Honoraria; Amgen, Boehringer Ingelheim, Amarin, Esperion.

PR.CVS.417: Heart Health in the Hotel California: Marijuana and Cardiovascular Disease

DESCRIPTION:

Marijuana and Cardiovascular Disease

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-139-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Katherine E Di Palo - None.

Robert Lee Page II - None.

Robert A Kloner - Other; Abiomed, Sanofi, Research Grant; OP2, TRDRP, NHLBI. Larry A Allen - Other; Janssen, Boston Scientific, Duke Clinical Research Institute, Amgen, Cytokinetics, Abbott, ACI Clinical, Research Grant; American Heart Association, PCORI, NIH.

PR.CVS.642: Mind Your Heart: Maintaining Cognitive Health and Understanding Cardiovascular Effects of Stress

DESCRIPTION:

This session is designed to elucidate the relationships between brain and heart health and to bring attention to AHA's new Brain Health Committee as well an upcoming scientific statement on the connection between psychosocial factors, lifestyle, and brain and heart health.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:
 Item

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Kushal Madan - None.

Marta Cortes-Canteli - Employment; Shin Poong Pharm. Co., Ltd..

Frank M Bengel - Honoraria; Abbott, GE Healthcare, Research Grant; Siemens.

Erica S Spatz - Other; Centers for Medicare and Medicaid Services.

Ahmed Tawakol - Honoraria; Esperion, Other; Actelion, Research Grant; Actelion, Genent

PR.CVS.689: Rapid Fire Great Debates in Preventive Cardiology

DESCRIPTION:

Rapid fire session with cases presented by FIT with pre ARS and post ARS voting by the audience

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Joshua Knowles - None. Albert Danso Osei - None. Amit Khera - None. Anum Saeed - None. John W McEvoy - None. Kirsten Bibbins-Domingo - None. Rina Mauricio - None. Vera A Bittner - Other Research Support; Astra Zeneca, DalCor, Esperion, Sanofi / Regeneron, Research Grant; The Medicines Company, Amgen. Raul Santos - Honoraria; Akcea, Ache, Astra Zeneca, Kowa, MSD, Merck, Novo Nordisk, Sanofi/Regeneron, PTC , Pfizer, Amgen. Jennifer G Robinson - Honoraria; Getz, Medicines Company, Novartis, Sanofi, Research Grant; Acasti, Amarin, Amgen, Astra-Zeneca, Esperion, Novartis, Novo Nordisk, Regeneron. Deepak L Bhatt - Research Grant; Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laborato.

Christie M Ballantyne - Other; Abbott Diagnostics, Akcea, Amgen, Arrowhead, Astra Zeneca, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Novartis, Novo Nordisk, Regeneron, Corvidia, Pfizer, Amarin, Denka Seiken, Sanofi-Synthelabo, Research Grant; Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic.

Brian A Ference - Honoraria; Merck, Sanofi, Regeneron, Novartis, Pfizer, Eli Lilly, Novo Nordisk, Medicines Company, Mylan, Daiichi Sankyo, Silence Therapeutics, Ionis Pharmaceuticals, dalCOR, CiVi Pharma, CiVi Pharma, American College of Cardiology, European Society of Cardiology, European Atherosclerosis Society, Amgen, Research Grant; Amgen, Esperion, Merck & Co, Novartis. Anurag Mehta - Other Research Support; Abraham J. and Phyllis Katz Foundation, Research Grant; American Heart Association.

QU.CVS.262: Encouraging Cardiovascular Innovation Without Breaking the Bank

DESCRIPTION:

A panel discussion with opportunities for audience participation related to encouraging innovation in cardiovascular therapeutics (Drugs/Devices) while continuing to ensure affordability and access. It will cover issues related to cost-effectiveness, affordability, access, and equity, while also including the innovator perspective on need for return on investment in R&D. One talk will cover issues related to rare disease drugs, another will cover biologic therapies, and one will examine the digital health economy.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias.

Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations: Dhruv Kazi - None.

Gregg C Fonarow - Honoraria; Abbott, Amgen, Janssen, Medtronic, Bayer, Merck, Novartis, Speaker/Speaker's Bureau; Novartis.

Ann Navar - Honoraria; Amgen, Astra Zeneca, Janssen, Esperion, Amarin, Sanofi, Regeneron, NovoNordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89Bio, and Pfizer, Research Grant; Regeneron and Sanofi, Amarin, Amgen, Janssen.

QU.CVS.562: Current Cardiovascular Controversies

DESCRIPTION:

Debates on hot topics in cardiovascular medicine.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.25 Contact Hours. Universal Program Number: JA0000134-0000-20-140-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Alejandra Miyazawa - None. Colleen K McIlvennan - None. James C Blankenship - None. John S Rumsfeld - None. Kelly C Epps - None. Michael Ho - None. Monika Sanghavi - None. Peter W Groeneveld - None. John F Heitner - Stock Shareholder; AMRN.

QU.CVS.568: Business of Healthcare: Changing Healthcare Payment Models and the Practicing Clinician

DESCRIPTION:

Changing healthcare payment models and the practicing clinician.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-141-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Sohail Khan - None.

Ty Gluckman - Expert Witness; Abbvie/Teva.

Khaldoun Tarakji - Honoraria; Medtronic, Boston Scientific, Alivecor.

Karen E Joynt Maddox - Other; United States Department of Health and Human Services, Research Grant; Commonwealth Fund, NIA, NHLBI.

QU.CVS.580: What Works: Evidence-Based Strategies to Reduce Disparities in Cardiovascular Care

DESCRIPTION:

Evidence-based strategies to reduce disparities in cardiovascular care.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-142-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Ciantel Blyler - None.

Carmen R Isasi - None.

Erin Michos - None.

Alan S Go - Research Grant; iRhythm Technologies, Novartis, National Heart, Lung and Blood Institute, National Institute on Aging, National Institute of Diabetes, Digestive and Kidney Diseases, Amarin.

QU.CVS.582: 2020 Update on Cardiovascular Clinical Guidelines

DESCRIPTION:

Clinical practice guidelines provide the compass for evidence-based care. This year's discussion will focus on the guideline-based management of a-fib, diabetes, lipid, VTE and PE.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.50 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.50 Contact Hours. Universal Program Number: JA0000134-0000-20-144-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Ankur Kalra - None.

Lin Y Chen - None.

Pamela Peterson - Other; American Heart Association, Research Grant; NHLBI.

Pedro Moreno - Speaker/Speaker's Bureau; Abiomed, Cuquerella medical, Amgen.

Neha Pagidipati - Honoraria; Esperion, Astra Zeneca, Boerhinger Ingelheim, Eli Lilly, Novo Nordisk, Research Grant; Amarin, Amgen, Novo Nordisk, Regeneron, Sanofi, Astra Zeneca, Baseline Study LLC, Boerhinger Ingelheim, Eli Lilly. Lale S. Tokgozoglu - Honoraria; Abbott, Amgen, Bayer, Mylan, Sanofi, Daiichi Sankyo, MSD, Servier, Pfizer, Recordati, Jansen.

Jay Giri - Other Research Support; Abbott/St Jude.

QU.CVS.793: 2020 ACC/AHA Performance Measures for Adult Heart Failure Care

DESCRIPTION:

This session is prompted by the soon to be released 2020 ACC/AHA Performance and Quality Measures for heart failure. It will describe the measures highlighting what is new as there have been significant changes. The session will discuss related issues to performance measurement including unintended consequences of performance measurement, outcomes vs process of care, patient reported outcomes, special populations of patients (advanced heart failure) and application of performance measures to all members of the healthcare team.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias.

Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-143-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Boback ZiaeianNone.Paul A HeidenreichNone.

Corrine Y JurgensEmployment; Boston College - Associate Professor.Clyde W Yancy Jr.Other; Abbott, Inc, JAMA Network.Barbara A PisaniStock Shareholder; Abbott, Medtronic, Glaxo Smith Kline.

QU.EC.514: A Contemporary Take on the Scientific Method: From An Idea to A Manuscript and Beyond

DESCRIPTION:

A contemporary take on the scientific method, from an idea to a manuscript and beyond.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date: 11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Colleen K	None.
McIlvennan	
Mike P Thompson	Other Research Support; Blue Cross Blue Shield of Michigan.
Brahmajee Kartik Nallamothu	Honoraria; American Heart Association, Ownership Interest; AngioInsight.
Adam P Bress	Research Grant; Novartis, Amarin, Amgen, NHLBI.
Ann Navar	Honoraria; Amgen, Astra Zeneca, Janssen, Esperion, Amarin, Sanofi, Regeneron, NovoNordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89Bio, and Pfizer,

Research Grant; Regeneron and Sanofi, Amarin, Amgen, Janssen.

SA.CVS.533: Heart Failure in 2020: How Has It Changed?

DESCRIPTION:

This session will catalogue the trends in heart failure management and transplantation throughout the decades from the medical and surgical perspectives.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliation
--

Charles Hill	None.
Leora Yarboro	None.
Marisa Cevasco	None.
William Hiesinger	None.
Arman Kilic	Other; Medtronic.

SA.CVS.534: A Multidisciplinary Approach to Hypertrophic Cardiomyopathy: From Bench to Operating Room

DESCRIPTION:

A multidisciplinary approach to hypertrophic cardiomyopathy, from bench to operating room.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Diana Anca	None.
Daniel Swistel	None.
Kent Rehfeldt	None.
Anjali T Owens	Other; Myokardia, Cytokinetics.

SA.CVS.535: Controversies in Ischemic Heart Disease. EXCEL Trial and Beyond

DESCRIPTION:

Controversies in ischemic heart disease. EXCEL trial and beyond.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

David Taggart	None.
Joanna Chikwe	None.
Mario F Gaudino	None.
Nadia Hensley	Other; Octapharma USA, Wolters Kluwers for uptodate.com.
Marc Ruel	Other Research Support; Edwards, Cryolife, Research Grant; Medtronic.
Husam H Balkhy	Other; Intuitive.

SA.CVS.553: Repair Don't Replace: Management of Structural Heart Disease

DESCRIPTION:

Percutaneous and surgical options in aortic and mitral valve disease will be discussed in interactive format.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Adanna Akujuo	None.
Hirokuni Arai	None.
Melissa Levack	None.
Pavan Atluri	Speaker/Speaker's Bureau; Edwards, Abbott, Medtronic.
Derek Ralph Brinster	Speaker/Speaker's Bureau; Terumo Aortic, Cook Medical.
Alina Nicoara	Speaker/Speaker's Bureau; Abbott.

SA.CVS.556: Percutaneous Interventions: Novel Therapies to Traditional Surgical Problems

DESCRIPTION:

Percutaneous interventions: novel therapies to traditional surgical problems.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

George Arnaoutakis	None.
Nimesh D Desai	None.
Tsuyoshi Kaneko	Speaker/Speaker's Bureau; Medtronic, Abbott Vascular, Baylis Medical, Edwards Lifesciences.
Isaac George	Honoraria; MitreMedical, Vdyne, CardioMech, Atricure.
Gilbert H Tang	Research Grant; W. L. Gore & Associates, Speaker/Speaker's Bureau: Abbott Structural Heart. Medtronic.

SA.CVS.557: Crisis Management in the Cardiac Surgical OR

DESCRIPTION:

Crisis management in the cardiac surgical OR.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliation
--

Amanda A. Fox	None.
Harendra Arora	None.
Jacob Gutsche	None.
Jacob Raphael	None.
Rebecca Aron	None.

SA.EC.503: Developing Your Career as an Academic Physician

DESCRIPTION:

In a rapid fire format, we will hear from a variety of academic physicians, both cardiac anesthesiologists and cardiac surgeons, at all levels, how they have navigated their career. In each presentation, we will hear the highs and lows, the dos and don't's.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliation
--

Anne Cherry	None.
Emily Jane MacKay	None.
Jennifer S Lawton	None.
Y Woo	None.
Sasha K Shillcutt	Ownership Interest; Brave Enough LLC.

Jochen Steppan	Research Grant; NIH.
Emily Methangkool	Honoraria; Anesthesia Patient Safety Foundation, Fresenius Kabi,
	Other Research Support; Edwards LifeSciences .
Elaine E Tseng	Other; Cryolife, Inc, UCSF, ReValve Med, Inc, Editor, Journal of Heart Valve Disease, Research Grant; NIH.

ST.CVS.397: Anticoagulation and Stroke Prevention for AF: Stroke Prophylaxis in Complicated Cases

DESCRIPTION:

In a rapid fire format, we will hear from a variety of academic physicians, both cardiac anesthesiologists and cardiac surgeons, at all levels, how they have navigated their career. In each presentation, we will hear the highs and lows, the dos and don't's.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias.

Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Original Release Date:	11/18/2020
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-145-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

May Kim-Tenser	Speaker/Speaker's Bureau; Chiesi.
Mahmut E Gurol	Research Grant; AVID (a wholly owned subsidiary of Eli Lilly),
	Boston Scientific Corporation, Pfizer.

Michael D Ezekowitz	Other; Sanofi, Abbott, Boston Scientific, Biogen, Anthos Therapeutic , Alta Thera.
Jodi Zilinski	Honoraria; Abbott Laboratories, Other; Medtronic.
Elaine Hylek	Honoraria; Anthos Therapeutics, Medtronic, MyoKardia, Bayer, Roche, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Other Research Support; Janssen, Abbott.

ST.CVS.541: Interventional Cardiology and Stroke Prevention: Part 1

DESCRIPTION:

Interventional cardiology and stroke prevention.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 0.75 Contact Hours. Universal Program Number: JA0000134-0000-20-146-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Vivek Y Reddy	Honoraria; Boston Scientific, Research Grant; Biosense-	
	Webster, Abbott, Stock Shareholder; Ablacon, Acutus	
	Medical, Affera.	
Srihari S Naidu	Other; Myokardia, Cytokinetics.	
Shephal K Doshi	Other Research Support; Conformal, Research Grant;	
	Abbott, Boston Scientific, Speaker/Speaker's Bureau; J & J.	

ST.CVS.597: Interventional Cardiology and Stroke Complications: Part 2

DESCRIPTION:

Interventional cardiology and stroke prevention.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:		
Fan Caprio	None.	
Matthew Maas	Research Grant; National Institutes of Health.	
Michael Chen	Other; Medtronic, Stryker, Penumbra, Microvention, Imperative Care, Speaker/Speaker's Bureau; Genentech.	

ST.CVS.684: Self-Efficacy, Resilience, Social Networks, and Policy to Tackle Disparities - Exploring the Superwoman Schema.

DESCRIPTION:

Self-Efficacy, resilience, social networks, and policy to tackle disparities - exploring the superwoman schema.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date: 11/18/2020 Last Review Date: November 2020 Termination Date: 11/17/2013 Joint Accreditation 11/18/2020 - 11/17/2023 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/facul	ty have declared financial interest(s) and/or affiliations
Crystal N Cene	None.
Karen P Williams	None.
Mahasin S Mujahid	None.
Susan Barnason	None.
Tiffany M Powell- Wiley	None.

The fellowing outbond /fe outbond declared financial in

VA.CVS.552: Tailored Therapy for PAD Comorbidities

DESCRIPTION:

Tailored therapy for PAD comorbidities.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-147-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Ryan Mays	None.
Tara I Chang	Other; Novo Nordisk, Janssen Research and Development,
	LLC, Research Grant; Satellite Health Care.
Naomi M Hamburg	Other; Merck, Sanifit, Amgen.

Marc P Bonaca	Honoraria; Amgen, Astrazeneca, Bayer, Janssen, Lexicon,
	Merck, NovoNordisk, Pfizer, Regeneron, Research Grant;
	Audentes, BIDMC, BMS, Lexicon, Medtronic, NovoNordisk,
	Regeneron, Amgen, Astrazeneca, Bayer, Janssen, Merck.
Joshua A Beckman	Honoraria; Astra Zeneca, Janssen, Glaxo Smith Kline, Amgen,
	Sanofi, Other; Novartis, Ownership Interest; Antidote
	Pharmaceuticals.

VA.CVS.559: BIG Questions for Pulmonary Embolism Intervention in 2020

DESCRIPTION:

A deep dive into the pressing issues in PE intervention, focused on how to study and clinically integrate new technology.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Susan Kahn	None.
Samuel Z Goldhaber	Other; Boehringer-Ingelheim, Janssen, Agile, Research Grant; Boehringer-Ingelheim, Bayer, BMS, Boston Scientific EKOS, Daiichi, Janssen, NHLBI.
Jay Giri	Other Research; Abbott/St Jude.
Gregory Piazza	Research Grant; BMS, Janssen, Portola, BTG/EKOS, Bayer.
Akhilesh Sista	Other Research Support; Penumbra, Inc., Research Grant; National Institutes of Health.

VA.CVS.565: Vascular Disease in Cancer Patients: Rise of the Vasculo-Oncologist

DESCRIPTION:

The session focuses on the growing vascular needs of cancer patients.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.75 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:		
Brett Carroll	None.	
Jeffrey Zwicker	Other; CSL, Pfizer/BMS, Parexel, Research Grant; Quercegen,	
	Incyte.	
Ana Barac	Honoraria; Bristol Myers Squibb, Takeda, Other; ACI Clinical.	

VA.CVS.579.2: PVD Workshop 2: What's New in Thoracic Aortic Aneurysm and Dissection

DESCRIPTION:

PVD Workshop.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

Original Release Date:	11/18/2020
Last Review Date:	November 2020

Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 – 11/17/2023
Term:	

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Alan Daugherty	None.
Jocelyn M Beach	None.
Melissa Levack	None.
Scott M Damrauer	Other; Calico Labs, Research Grant; Renalytix AI, U.S. Department of Veterans Affairs.
Aaron W Aday	Other Research Support; OptumCare.

VA.CVS.609: Perioperative Management of Anticoagulants and Antiplatelet Therapy

DESCRIPTION:

Perioperative management of anticoagulants and antiplatelet therapy.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:
Last Review Date:	November 2020
Termination Date:	11/17/2013
Joint Accreditation	11/18/2020 - 11/17/2023
Term:	

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-148-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

-	
James Douketis	Honoraria; Janssen, BMS-Pfizer, Leo Pharma, Sanofi, Servier.
Geoffrey Barnes	Honoraria; Acelis Connected Helath, Portola, AMAG
	Pharmaceuticals, BMS/Pfizer, Janssen.
Deborah Siegal	Honoraria; Leo Pharma, BMS-Pfizer, Bayer, Aspen Pharma,
	Portola.

Research Grant; Astra Zeneca, Jannsen.

Dominick Joseph Angiolillo

VA.EC.518: Incorporating Vascular Medicine into Other Training Pathways

DESCRIPTION:

This session highlights how vascular medicine training can and should be integrated into specialty training for general cardiology, vascular surgery, general internal medicine, and interventional radiology.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 0.50 contact hours.

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Melissa Kirkwood	None.
Sanjay Misra	None.
Aaron W Aday	Other Research Support; OptumCare.

VA.ME.583: Disruptive Science in PAD: Data, Drugs, and Devices

DESCRIPTION:

Discussion of medical and interventional therapies in peripheral artery disease, including a debate on the safety of drug coated devices and regulatory issues related to meta-analysis data.

PARTICIPATION AND SUCCESSFUL COMPLETION:

Successful completion of this CE activity includes the following: Register and view the course online. View the content in its entirety. Complete a post-test with a minimum passing score. Complete a survey of your learning experience. Claim your CME/CE Certificate.

TARGET AUDIENCES:

Physicians Physician Assistants Nurse Practitioners Nurses Pharmacists

LEARNING OBJECTIVES:

At the conclusion, participants should be able to:

Translational Science

Discuss the adaptation and testing of fundamental scientific discoveries to the diagnosis and treatment of cardiac and vascular disease in patients.

Basic Science

Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias. Discuss basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.

Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.

Clinical Science

Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.

Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke

Population Science

Recognize emerging trends in the distribution of cardiovascular disease and stroke and their impact on public health.

Evaluate the impact of new diagnostic and therapeutic strategies on health costs and outcomes.

ACCREDITATION STATEMENTS:

 Original Release Date:
 11/18/2020

 Last Review Date:
 November 2020

 Termination Date:
 11/17/2013

 Joint Accreditation
 11/18/2020 – 11/17/2023

 Term:

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement - Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement - Nurse Practitioners

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit[™] from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement - Pharmacists

ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-149-H04-P

DISCLOSURE STATEMENT

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The following authors/faculty have declared financial interest(s) and/or affiliations:

Sara Royce	None.
William S Jones	Honoraria; Bayer, Janssen Pharmaceuticals, Research Grant;
	Bristol Myers Squibb, Medtronic.

Scott M Damrauer	Other; Calico Labs, Research Grant; Renalytix AI, U.S. Department of Veterans Affairs.
Sue Duval	Other; VIVA Physicians.
Sonia Anand	Honoraria; Bayer AG.
Konsantinos Katsanos	Honoraria; Concept Medical, Research Grant; Abbott, RONTIS , Medalliance.
Joshua A Beckman	Honoraria; Astra Zeneca, Janssen, Glaxo Smith Kline, Amgen, Sanofi, Other; Novartis, Ownership Interest; Antidote Pharmaceuticals.
Eric A Secemsky	Honoraria; Medtronic, Philips, CSI, Abbott, Janssen, Research Grant; AstraZeneca, Medtronic, Philips, Cook, BD, Boston Scientific, CSI, Speaker/Speaker's Bureau; Cook, BD.